Note: Descriptions are shown in the official language in which they were submitted.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED
CANNABINOIDS AND/OR PURIFIED TERPENES
TECHNICAL FIELD
This disclosure relates to the cannabis industry. In particular, this
disclosure relates to
compositions and formulations comprising new, purposefully engineered
combinations of purified
compounds.
BACKGROUND
The word "cannabis" refers to a genus of flowering plants. Plants of genus
cannabis include
several species, including Cannabis sativa, Cannabis indica, and Cannabis
ruderalis. There is a long
history of cultivating plants of genus cannabis for hemp fibers, seeds and
seed oils, medicinal
purposes, and recreational activities.
According to some accounts, cannabis is composed of at least 483 known
chemical
compounds, which include cannabinoids, terpenoids, flavonoids, nitrogenous
compounds, amino
acids, proteins, glycoproteins, enzymes, sugars and related compounds,
hydrocarbons, alcohols,
aldehydes, ketones, acids, fatty acids, esters, lactones, steroids, terpenes,
non-cannabinoid phenols,
vitamins, and pigments.
Cannabinoids are of particular interest for research and commercialization.
Most
extractions of cannabis plant matter aim to extract cannabinoids, particularly
tetrahydrocannabinol
(THC). THC is useful for relieving pain, treating glaucoma, and relieving
nausea. THC is also
gaining immense popularity as a recreational drug substance. Usually,
cannabinoids are extracted
from the cannabis plant as part of a crude mixture, combined with other
chemical compounds found
in the cannabis plant.
Despite developments in isolating a handful of the cannabinoids and terpenes
found in
cannabis plants, no work has been done in formulating compositions having
particular
combinations containing purified or isolated forms of these compounds. Some of
the less common
cannabinoids have neither been isolated nor studied alone or in any
combination. Additionally,
there has been little or no work developing compositions having purposefully
engineered,
repeatable, consistent, and dependable ratios of purified cannabinoids. In
particular, there have
been no developments in combining a cannabinoid with a purified terpene.
There exists a need for compositions comprising new man-made combinations of
purified
cannabis components. In particular, there exists a need for compositions
comprising new
combinations of at least one cannabinoid and at least one purified terpene.
1
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
DETAILED DESCRIPTION
Disclosed herein are new compositions comprising purified cannabinoids and/or
purified
terpenes. In one embodiment of this disclosure, the compositions comprise a
first purified
cannabinoid and a first purified terpene. In one embodiment of this
disclosure, the compositions
comprise a first purified cannabinoid and a second purified cannabinoid. In
one embodiment of this
disclosure, the compositions comprise a first purified cannabinoid, a second
purified cannabinoid,
and a first purified terpene. In one embodiment of this disclosure, the
compositions comprise a first
purified cannabinoid, a first purified terpene, and a second purified terpene.
The compositions disclosed herein are purposefully formulated to provide man-
made, non-
naturally occurring combinations, concentrations, and/or ratios of compounds
sometimes found in
naturally occurring cannabis plants.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
ratio of a first purified cannabinoid and a first purified terpene. In one
embodiment, the
compositions disclosed herein include a non-naturally occurring concentration
of a first purified
cannabinoid and a first purified terpene.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
ratio of a first purified cannabinoid and a second purified cannabinoid. In
one embodiment, the
compositions disclosed herein include a non-naturally occurring concentration
of a first purified
cannabinoid and a second purified cannabinoid.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
ratio of a first purified cannabinoid, a second purified cannabinoid, and a
first purified terpene. In
one embodiment, the compositions disclosed herein include a non-naturally
occurring
concentration of a first purified cannabinoid, a second purified cannabinoid,
and a first purified
terpene.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
ratio of a first purified cannabinoid, a second purified cannabinoid, and a
third purified cannabinoid.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
concentration of a first purified cannabinoid, a second purified cannabinoid,
and a third purified
cannabinoid.
In one embodiment, the compositions disclosed herein include a non-naturally
occurring
ratio of a first purified terpene, a second purified terpene, and a first
purified cannabinoid. In one
embodiment, the compositions disclosed herein include a non-naturally
occurring concentration of
a first purified terpene, a second purified terpene, and a first purified
cannabinoid.
In one embodiment of this disclosure, the compositions comprise an unnaturally
occurring
ratio of 10:1 - 1:1 of a purified cannabinoid to purified terpene.
2
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of this disclosure, the compositions comprise an unnaturally
occurring
ratio of 10:1 - 5:1 of a purified cannabinoid to purified terpene.
In one embodiment of this disclosure, the compositions comprise an unnaturally
occurring
ratio of greater than 10:1 of a purified cannabinoid to purified terpene.
Disclosed herein are compositions comprising:
a first purified cannabinoid; and
a compound chosen from a second purified cannabinoid or a first purified
terpene,
wherein the said composition is substantially free from cellulose.
As used within the context of this application, the term "purified" means
extracted, isolated,
and/or separated from other compounds, formulations, compositions, matter,
and/or mass. In one
embodiment, the term "purified" refers to a cannabinoid that is separated from
the plant matter
from which it was derived.
In one embodiment, the term "purified" refers to a cannabinoid (a "purified
cannabinoid")
that is separated from other cannabinoids that were present in the plant
matter from which it was
derived. In one embodiment, the term "purified" refers to a cannabinoid (a
"purified cannabinoid")
that is separated from terpenes that were present in the plant matter from
which it was derived. In
one embodiment, the term "purified" refers to a cannabinoid (a "purified
cannabinoid") that is
separated from secondary compounds that were present in the plant matter from
which it was
derived. In one embodiment, the term "purified" refers to a cannabinoid (a
"purified cannabinoid")
that is separated from all material that was present in the plant matter from
which it was derived.
In one embodiment, the term "purified" refers to a terpene (a "purified
terpene") that is
separated from other cannabinoids that were present in the plant matter from
which it was derived.
In one embodiment, the term "purified" refers to a terpene (a "purified
terpene") that is separated
from terpenes that were present in the plant matter from which it was derived.
In one embodiment,
the term "purified" refers to a terpene (a "purified terpene") that is
separated from secondary
compounds that were present in the plant matter from which it was derived. In
one embodiment,
the term "purified" refers to a terpene (a "purified terpene") that is
separated from all material that
was present in the plant matter from which it was derived.
Within the context of this disclosure, purified compounds may be purposely
formulated
with other compounds at various levels of purity. For example, depending on
the desired outcome,
a particular cannabinoid or terpene may be formulated with other molecules
when it is 60-65%
pure, 65-70% pure, 70-75% pure, 75-80% pure, 80-85% pure, 85-90% pure, 90-95%
pure, 95-99%
pure, 99-99.9% pure, 99.9+%, or greater than 99% pure. Provided that the
ingredients used for
purposeful formulation are purified prior to the said purposeful formulation,
the act of subsequently
formulating them does render them not "purified" within the context of an
ingredient list.
3
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, purified means "substantially free" from other material,
e.g.,
compounds, particles, vegetative material, plant derived substances, solvents,
etc. In one example,
the term "purified" refers to a compound purified from a crude extract, such
as a biologically
derived substance or BDS, thereby resulting in a significant difference
between the purified
compound and the extract. In one embodiment, substantially free means that the
compound
comprises no (or insignificant amounts) of other materials.
Within the context of this disclosure, the term "plant" refers to the whole
plant and parts of
the plant, e.g., leaves, roots, bark, flower, etc. The term plant also
encompasses a dried plant and
dried parts of the plant.
Within the context of this disclosure, where a compound comprises stereogenic
centers, the
term "purified" includes isolated stereoisomers and also mixtures of
stereoisomers, provided that
the compound having the stereoisomers is free from other compounds having
different atomic
connectivity.
As used within the context of this application, the term "manmade" means
engineered or
purposefully created by a human in contrast to naturally "in nature" without
human influence. In
one embodiment, manmade compositions are formulations made by combining
naturally occurring
molecules in a new unnatural way, for example by separating the individual
chemical components
of a plant and then recombining some of those components to achieve different
concentrations
and/or ratios of those components. In one embodiment, manmade compositions are
formulations
made with one or more processes in a chemical extraction and purification lab.
The properties of compositions of this disclosure-- made by purposefully
combining
purified compounds with concentrations, combinations and/or ratios¨differ from
previously
existing technology, such as extracts or other processed materials, e.g.,
biological drug substance,
medically grade plant extracts, etc.
In one embodiment, purification comprises using various solvents, e.g.,
ethanol, butane,
methane, carbon dioxide, ice, water, steam. In one embodiment, purification
comprises various
techniques, e.g., chromatography, crystallization, filtration, centrifuge,
etc. or various
combinations of said techniques. In one embodiment, purification comprises
extracting
cannabinoids and other plant molecules from plants bred to express desired
cannabinoid and/or
terpene profiles for purity.
As used herein, the term "cellulose" means an organic compound with the
formula
(C6H1005).. In one embodiment, the phrase "substantially free from cellulose"
is intended to
distinguish purified components of naturally occurring plants (for example the
cannabis plant) from
the isolated chemical compounds that are free from plant material, such as
cellulose.
As used herein, the term "naturally occurring" refers to materializing,
arising, happening,
or synthesizing in nature. In one embodiment, naturally occurring refers to a
secondary compound
4
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
synthesized within a plant. In one embodiment, naturally occurring refers to a
collection of
cannabinoids synthesized within a plant of genus cannabis. In one embodiment,
naturally occurring
refers to the concentrations of compounds within a plant. In one embodiment,
naturally occurring
refers to the concentration of cannabinoids within a plant of genus cannabis.
In one embodiment,
naturally occurring refers to the ratio of secondary compounds within a plant.
In one embodiment,
the naturally occurring refers to the ratio of a first cannabinoid to a second
cannabinoid within a
plant of genus cannabis.
As used herein, the term "naturally occurring ratio" refers to the proportion
of one
compound or compounds in relation to another compound or compounds within a
plant of genus
cannabis. In one embodiment, the naturally occurring ratio is the amount of a
cannabinoid in
relation to the amount of a cannabinoid within a plant of genus cannabis. In
one embodiment, the
naturally occurring ratio is the amount of a cannabinoid in relation to the
amount of a terpene within
a plant of genus cannabis. In one embodiment, the naturally occurring ratio is
the amount of a
cannabinoid in relation to the amount of a terpene within a flower of genus
cannabis. In one
embodiment, the naturally occurring ratio is the amount of a cannabinoid in
relation to the amount
of a terpene within a plant extract of genus. In one embodiment, the naturally
occurring ratio is the
amount of a cannabinoid in relation to the amount of a terpene within a
formulation made from
plant extract of genus cannabis.
In one embodiment, the naturally occurring ratio is expressed as a molar
ratio. In one
embodiment, the naturally occurring ratio is expressed as a mass. In one
embodiment, the mass
and/or molar ratio is measured by chromatography and/or spectroscopy.
As used herein, the term "unnaturally occurring ratio" refers to the
proportion of one
compound or compounds in relation to another compound or compounds in a
composition created
by a human. In one embodiment, the unnaturally occurring ratio is the amount
of a cannabinoid in
relation to a terpene and is not observed in a plant of genus cannabis. In one
embodiment, the
unnaturally occurring ratio is expressed as a molar ratio. In one embodiment,
the unnaturally
occurring ratio is expressed as a mass. In one embodiment, the mass and/or
molar ratio is measured
by chromatography and/or spectroscopy.
In one embodiment, the unnaturally occurring ratio is the amount of a
cannabinoid in
relation to the amount of a terpene within a composition formulated by a human
not observed in a
plant of genus cannabis. In one embodiment, the unnaturally occurring ratio is
the amount of a
cannabinoid in relation to the amount of a second cannabinoid within a
composition formulated by
a human not observed in a plant of genus cannabis.
As used herein, the term "naturally occurring concentration" refers to the
amount of a
compound or compounds in relation to an entire naturally occurring reference
sample. In one
embodiment, the naturally occurring concentration is the amount of a
cannabinoid in a sample of a
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
plant of genus cannabis. In one embodiment, the naturally occurring
concentration is the amount
of a cannabinoid within the dried, or cured, flower of a plant of genus
cannabis. In one embodiment,
the naturally occurring concentration is the amount of a cannabinoid within a
crude extract of a
plant of genus cannabis.
In one embodiment, the naturally occurring concentration is the amount of a
terpene in a
sample of a plant of genus cannabis. In one embodiment, the naturally
occurring concentration is
the amount of a terpene within the dried, or cured, flower of a plant of genus
cannabis. In one
embodiment, the naturally occurring concentration is the amount of a terpene
within a crude extract
of a plant of genus cannabis. In one embodiment, the unnaturally occurring
concentration is
measured by moles and expressed as Molarity. In one embodiment, the naturally
occurring
concentration is measured by percent mass.
As used herein, the term "unnaturally occurring concentration" refers to the
amount of a
compound or compounds in relation to an entire sample within a manmade
composition. In one
embodiment, the unnaturally occurring concentration is the amount of a
cannabinoid in relation to
the total composition. In one embodiment, the unnaturally occurring
concentration is the amount
of a terpene in relation to the total composition. In one embodiment, the
unnaturally occurring
concentration is measured by moles and expressed as Molarity. In one
embodiment, the unnaturally
occurring concentration is measured by percent mass.
As used herein, the term "total mass" refers to the entire amount of matter
for a given
reference sample. In one embodiment, the total mass is measured by molecular
mass.
The term "pharmacological fingerprint" refers to a collection of data about
the activity of a single
cannabinoid or terpene, or any combination of cannabinoids and/or terpenes, at
one or more targets
in the human body, e.g., a cannabinoid receptor, e.g., CB1, CB2, GPR55, 5HT-
1A, 5HT-2A,
TRPV1, serotonin receptor, or jt-opioid receptor. The compositions disclosed
herein were created
using cellular (e.g., pharmacological fingerprint) and/or clinical data to
select and combine
particular combinations of compounds having new properties.
As used herein, the term "potency" refers to the power, influence, activity,
or effectiveness
of the compositions disclosed herein at a particular cellular receptor. In one
embodiment, potency
is measured by the response of a subject. In one embodiment, potency is
measured by the cellular
reactivity of a cannabinoid at a receptor, e.g., CB1, CB2, GPR55, 5HT-1A, 5HT-
2A, TRPV1,
serotonin receptor, or jt-opioid receptor. In one embodiment, potency refers
to the ECSO. In one
embodiment, potency refers to amplitude of response.
As used herein, the term "agonism" refers to the effect of a compound,
agonist, activating
a receptor and inducing a response. In one embodiment, the receptor is chosen
from CB1, CB2,
GPR55, 5HT-1A, 5HT-2A, TRPV1, serotonin receptor, or -opioid receptor. In one
embodiment,
the agonist is a cannabinoid. In one embodiment, the agonist is a terpene.
6
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "antagonism" refers to two or more compounds in
combination
having an effect. In one embodiment, antagonism is a composition comprising a
cannabinoid
affecting another cannabinoid, i.e., a cannabinoid affecting the binding of
another cannabinoid to
a receptor. In one embodiment, antagonism is a composition comprising a
terpene affecting another
cannabinoid, i.e., a terpene affecting the binding of another cannabinoid to a
receptor.
In one embodiment, the compositions disclosed herein modify the potency of an
endogenous neurotransmitter within an organism, e.g., a serotonin receptor, an
adrenergic receptor,
a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a
histaminergic receptor, a
cholinergic receptor, an opioid receptor, a glycinergic receptor, etc., at one
or more of its
endogenous receptors, e.g., serotonin, norepherine, adrenaline, dopamine, etc.
In one embodiment, the compositions disclosed herein increase the potency of
serotonin at
the 5-HTIA receptor. In one embodiment, the compositions disclosed herein
increase the potency
of serotonin at the 5-HT2A receptor. In one embodiment, the compositions
disclosed herein increase
the potency of serotonin at the 5-HT 1A receptor and decrease the potency of
serotonin at the 5-HT2A
receptor. In one embodiment, the compositions disclosed herein decrease the
potency of serotonin
at the 5-HT 1A receptor and increase the potency of serotonin at the 5-HT2A
receptor.
For example, formulations of this disclosure have been achieved by expressing
the human
components of the endocannabinoid system (or other known targets of cannabis
pharmacology) in
cultured cells and treating the cells with serial dilutions of individual
compounds or combinations
of compounds in order to determine the EC5Os of each component at each target
individually, and
whether adding other components shifts either the amplitude of the response or
the effective
concentration (EC50) of the response.
As used herein, the term "EC50" means "half maximal effective concentration,"
which
refers to the concentration of a formulation (e.g., a cannabinoid, terpene, or
combination thereof)
inducing a response halfway between the baseline and maximum after a specified
exposure time.
In one embodiment, the EC50 value is used as a measure of a drug's potency.
The EC50 of a graded dose response curve represents the concentration of a
compound
where 50% of its maximal effect is observed. The EC50 of a quantal dose
response curve represents
the concentration of a compound where 50% of the population exhibit a
response, after a specified
exposure duration.
As used herein, the term "amplitude of response" refers to the magnitude of
reactivity to
the compositions disclosed herein. In one embodiment, the amplitude of
response is the reaction of
a receptor, e.g., CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, serotonin receptor,
or il-opioid
receptor, to a sample administered thereto.
For example, in one system, D9-THC activity at cannabinoid receptor 1 (CB1)
has a
consistent EC50 of around 1 micromolar, and a 40 ¨ 50% amplitude of response
compared to a
7
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
known, synthetic full agonist (CP-55,940). The lower response of CB1 to THC
relative to a full
agonist is why THC is referred to as a "partial agonist" of the CB1 receptor.
In some embodiments, the purposefully engineered formulations disclosed herein
were
developed by establishing the EC50 of THC at CB1 numerous times and
determining EC50s of
THC in a background of constant concentrations of other cannabinoids and
terpenes. This is one
example of a method for determining how particular cannabis components my
either synergize,
add to, or compete with the THC response itself
Using these purposefully engineered combinations (rather than naturally
occurring
combinations) provide a user with quantifiable control over the underlying
pharmacology and
biochemistry responsible for the observed physical and psychological effects.
Accordingly, the
compositions disclosed herein provide unprecedented control over the effects
of cannabinoids
and/or terpenes on the user.
In one embodiment, the composition provides a decrease in the EC50 for either
or both of
a first purified cannabinoid and/or a second purified cannabinoid at a
particular receptor.
In one embodiment, the composition provides an increase in the EC50 for either
or both of the
purified cannabinoid and/or a second purified cannabinoid at a particular
receptor, for example the
CB1, CB2 GPR55, 5HT-1A, 5HT-2A, TRPV1, and/or il-opioid receptor.
In one example, the compositions disclosed herein change the EC50 of THC at
the CB1
receptor. In one embodiment, by using the synergistic compositions disclosed
herein, the EC50 of
THC is modulated, thereby providing new beneficial properties.
In one example, THC activity at the CB1 receptor has a consistent EC50 of
about 1
micromolar and a 40 ¨ 50% amplitude of response compared to a known, synthetic
full agonist
(e.g., CP-55,940).
In one example, the synergistic benefits of the compositions disclosed herein
can be
demonstrated by measuring the EC50 of THC at CB1 alone and then comparing it
to the EC50 of
THC at CB1 in the presence of other cannabinoids and terpenes.
In one example, the disclosed compositions provide a synergistic effect
relative to a
reference cannabinoid administered alone. In one example, the disclosed
compositions add to the
effects of a reference cannabinoid. In one example, the disclosed compositions
compete with a
reference cannabinoid at the CB1 receptor.
In one example, the disclosed compositions provide a synergistic effect
relative to THC alone.
In one example, the disclosed compositions add to the effects of THC alone.
As such, the compositions disclosed herein provide for methods of increasing
the response
of THC at the CB1 receptor (relative to THC alone) comprising administering
THC in concert with
a terpene.
8
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the purified terpene is chosen from Limonene, Nerolidol,
Beta-
Myrcene, Linalool, Alpha-Caryophyllene, Beta-Caryophyllene, Alpha-Pinene, Beta-
Pinene,
Alpha-Bisabolol, Delta-3 -Carene, Borneo!, p-Cymene, Eucalyptol, Alpha-
Humulene, Alpha-
Terpineol, Terpinolene, Pulegone, Camphene, or Geraniol.
Disclosed herein are methods of increasing the potency at a receptor, e.g.
CB1, CB2
GPR55, 5HT-1A, 5HT-2A, TRPV 1, serotonin receptor, -opioid receptor, etc., of
a first purified
cannabinoid in concert with a first purified terpene. In one embodiment,
increasing the potency at
a receptor comprises a second purified cannabinoid. In one embodiment,
increasing the potency at
a receptor comprises a second purified terpene.
In one embodiment, the compositions disclosed herein provide methods of
increasing the
response of THC at the CB1 receptor (relative to THC alone) comprising
administering THC in
concert with a terpene. In one example the method of increasing THC potency
comprises
administering THC in concert with alpha-humulene. In one example the method of
increasing THC
potency comprises administering THC in concert with linalool. In one example
the method of
increasing THC potency comprises administering THC in concert with nerolidol.
In one example
the method of increasing THC potency comprises administering THC in concert
with limonene. In
one example the method of increasing THC potency comprises administering THC
in concert with
alpha-terpineol. In one example the method of increasing THC potency comprises
administering
THC in concert with beta-pinene. In one example the method of increasing THC
potency comprises
administering THC in concert with p-cymene. In one example the method of
increasing THC
potency comprises administering THC in concert with eucalyptol.
In one embodiment, the compositions disclosed herein provide methods of
increasing the
response of THC at the CB1 receptor (relative to THC alone) comprising
administering THC in
concert with a second cannabinoid. In one example the method of increasing THC
potency
comprises administering THC in concert with CBC. In one example the method of
increasing THC
potency comprises administering THC in concert with CBG. In one example the
method of
increasing THC potency comprises administering THC in concert with THCV. In
one example the
method of increasing THC potency comprises administering THC in concert with
CBD.
In one example, the disclosed compositions compete with THC at the CB1
receptor.
In one example, the EC50 of THC at CB1 is decreased (relative to THC alone) by
formulating a composition comprising purified THC and a purified terpene
chosen from Limonene,
Nerolidol, Beta-Myrcene, Linalool, Alpha-Caryophyllene, Beta-Caryophyllene,
Alpha-Pinene,
Beta-Pinene, Alpha-Bisabolol, Delta-3-Carene, Borneo!, p-Cymene, Eucalyptol,
Alpha-Humulene,
Alpha-Terpineol, Terpinolene, Pulegone, Camphene, or Geraniol.
In one example, the EC50 of THC at CB1 is increased (relative to THC alone) by
formulating a composition comprising purified THC and beta-caryophyllene.
9
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the phrase "comprising
a purified
THC and a purified terpene" means that the composition includes between about
0.5% to about
10% combined terpene content.
An exemplary non-limiting terpene is linalool. One embodiment of this
disclosure
comprises 0.5-1% purified linalool. One embodiment of this disclosure
comprises 1-2% purified
linalool. One embodiment of this disclosure comprises 2-5% purified linalool.
One embodiment of
this disclosure comprises 5-10% purified linalool.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Limonene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Nerolidol.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Beta-Myrcene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Linalool.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Alpha-Caryophyllene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Beta-Caryophyllene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Alpha-Pinene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Beta-Pinene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Alpha-Bisabolol.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Delta-3-Carene.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Borneo'.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Eucalyptol.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified Alpha-Terpineol.
In one example, the EC50 of THC at CB" is decreased by formulating a
composition
comprising purified THC and purified p-Cymene.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the EC50 of THC at CB1 is decreased by formulating a
composition
comprising purified THC and purified Alpha-Humulene.
In one example, the EC50 of THC at CB1 is decreased by formulating a
composition
comprising purified THC and purified Terpinolene.
In one example, the EC50 of THC at CB1 is decreased by formulating a
composition
comprising purified THC and purified Pulegone.
In one example, the EC50 of THC at CB1 is decreased by formulating a
composition
comprising purified THC and purified Camphene.
In one example, the EC50 of THC at CB1 is decreased by formulating a
composition
comprising purified THC and purified Geraniol.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB1
while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while decreasing the EC50 of a second cannabinoid at CB1.
11
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at CB2
while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at GPR55.
12
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions increase the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB1 while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while increasing the EC50 of a second cannabinoid at CB1.
13
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
CB2 while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at GPR55.
14
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while increasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-1A while decreasing the EC50 of a second cannabinoid at 5HT-2A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while increasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at CB1.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at CB2.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at GPR55.
In one example, the disclosed compositions decrease the EC50 of a first
cannabinoid at
5HT-2A while decreasing the EC50 of a second cannabinoid at 5HT-1A.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Limonene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Nerolidol.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Beta-Myrcene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Linalool.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Alpha-Caryophyllene.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Beta-Caryophyllene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Alpha-Pinene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Beta-Pinene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Alpha-Bisabolol.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Delta-3-Carene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Borneo'.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Eucalyptol.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Alpha-Terpineol.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified p-Cymene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Alpha-Humulene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Terpinolene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Camphene.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Geraniol.
In one example, the Amplitude of Response of THC at CB1 is decreased by
formulating a
composition comprising purified THC and purified Pulegone.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Limonene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Nerolidol.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Beta-Myrcene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Linalool.
16
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Alpha-Caryophyllene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Beta-Caryophyllene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Alpha-Pinene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Beta-Pinene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Alpha-Bisabolol.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Delta-3-Carene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Borneo'.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Eucalyptol.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Alpha-Terpineol.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified p-Cymene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Alpha-Humulene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Camphene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Terpinolene.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Geraniol.
In one example, the Amplitude of Response of THC at CB1 is increased by
formulating a
composition comprising purified THC and purified Pulegone.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
17
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at CB1.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at CB1.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
18
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
19
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions increase the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB1 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at CB1.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while increasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
21
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at CB1.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at CB2 while decreasing the Amplitude of Response of a second
cannabinoid at 5HT-
2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while increasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at GPR55 while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
22
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while increasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-1A while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-2A.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while increasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
23
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
CBI.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
CB2.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
GPR55.
In one example, the disclosed compositions decrease the Amplitude of Response
of a first
cannabinoid at 5HT-2A while decreasing the Amplitude of Response of a second
cannabinoid at
5HT-1A.
In one illustration of the above embodiments, the EC50 of THC at CB1 is
decreased within
a composition comprising THC and Alpha-Humulene.
In one embodiment, the EC50 of THC at CB1 is decreased to between about 0.1
micromolar to
about 0.5 micromolar.
In one illustration of the above embodiments, the EC50 of THC at CB1 is
decreased within
a composition comprising THC and Linalool.
In one embodiment, the EC50 of THC at CB1 is decreased to between about 0.05
micromolar to
about 0.2 micromolar.
The above described examples of cellular effect can be further correlated with
the results
from the clinical studies, such as those exemplified in this application.
As used herein, the term "cannabinoid" refers to a compound belonging to a
class of
secondary compounds commonly found in plants of genus cannabis. In one
embodiment, the
cannabinoid is found in a plant, e.g., a plant of genus cannabis, and is
sometimes referred to as a
phytocannabinoid. In one embodiment, the cannabinoid is found in a mammal,
sometimes called a
endocannabinoid. In one embodiment, the cannabinoid is made in a laboratory
setting, sometimes
called a synthetic cannabinoid. In one embodiment, the cannabinoid acts upon a
cellular receptor,
such as a G-coupled protein receptor (e.g., a serotonin receptor, a
cannabinoid receptor, TRPV1,
an opioid receptor, etc.) thereby causing a response on the brain or body. In
one embodiment, the
cannabinoid affects the activity of other compounds at one or more receptors
by acting as an
agonist, partial agonist, inverse agonist, antagonist, etc.
In many cases, a cannabinoid can be identified because its chemical name will
include the
text string "*cannabi* in the name.
24
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this application, where reference is made to a
particular cannabinoid,
each of the acid and/or decarboxylated forms are contemplated as both single
molecules and
mixtures.
Examples of cannabinoids include, but are not limited to, Cannabigerolic Acid
(CBGA),
Cannabigerolic Acid monomethylether (CBGAM), Cannabigerol (CBG), Cannabigerol
monomethylether (CBGM), Cannabigerovarinic Acid (CBGVA), Cannabigerovarin
(CBGV),
Cannabichromenic Acid (CBCA), Cannabichromene (CBC), Cannabichromevarinic Acid
(CBCVA), Cannabichromevarin (CBCV), Cannabidiolic Acid (CBDA), Cannabidiol
(CBD),
Cannabidiol monomethylether (CBDM), Cannabidiol-C4 (CBD-C4), Cannabidivarinic
Acid
(CBDVA), Cannabidivarin (CBDV), Cannabidiorcol (CBD-Ci),
Tetrahydrocannabinolic acid A
(THCA-A), Tetrahydrocannabinolic acid B (THCA-B), Tetrahydrocannabinolic Acid
(THCA),
Tetrahydrocannabinol (THC), Tetrahydrocannabinolic acid C4 (THCA-C4),
Tetrahydrocannbinol
C4 (THC-C4), Tetrahydrocannabivarinic acid (THCVA), Tetrahydrocannabivarin
(THCV),
Tetrahydrocannabiorcolic acid (THCA-Ci), Tetrahydrocannabiorcol (THC-Ci), A7-
cis-iso-
tetrahydrocannabivarin, A8-tetrahydrocannabinolic acid (48-THCA),
Cannabivarinodiolic
(CBNDVA), Cannabivarinodiol (CBNDV), A8-teirahydrocannabinol (A8-THC), A9-
tetrahy droc annabinol (A9-THC), Cannabicyclolic acid (CBLA), Cannabicyclol
(CBL),
Cannabicyclovarin (CBLV), Cannabielsoic acid A (CBEA-A), Cannabielsoic acid B
(CBEA-B),
Cannabielsoin (CBE), Cannabivarinselsoin (CBEV), Cannabivarinselsoinic Acid
(CBEVA),Cannabielsoic Acid (CBEA), Cannabielvarinsoin (CBLV),
Cannabielvarinsoinic Acid
(CBLVA), Cannabinolic acid (CBNA), Cannabinol (CBN), Cannabivarinic Acid
(CBNVA),
Cannabinol methylether (CBNM), Cannabinol-C4 (CBN-C4), Cannabivarin (CBV),
Cannabino-C2
(CBN-C2), Cannabiorcol (CBN-Ci), Cannabinodiol (CBND), Cannabinodiolic Acid
(CBNDA),
Cannabinodivarin (CBDV), Cannabitriol (CBT), 10-Ethoxy-9-hydroxy-e-
tetrahydrocannabinol,
8,9-Dihydroxy-A6a("-tetrahydrocannabinol (8,9-Di-OH-CBT-05), Cannabitriolvarin
(CBTV),
Ethoxy-cannabitriolvarin (CBTVE), Dehydrocannabifuran (DCBF), Cannbifuran
(CBF),
Cannabichromanon (CBCN), Cannabicitran (CBT), 1 0-0xo-A6a(1 a)-tetrahydroc
annabi ol
(OTHC), A9-cts4etrahydrocatinabinol (cis-THC), Cannabiripsol (CBR), 3,4,5,6-
tetrahydro-7-
hydroxy-alpha-alpha-2-trimethy1-9-n-propy1-2,6-methano-2H- 1 -benzoxocin-5 -
methanol (OH-iso-
HHCV), Trihydroxy-delta-9-tetrahydrocannabinol (tri0H-THC), Yangonin,
Epigallocatechin
gallate, Dodeca-2E, 4E, 8Z, 10Z-tetraenoic acid isobutylamide, and Dodeca-
2E,4E-dienoic acid
isobutylamide.
In one embodiment, the purified cannabinoid is chosen from THC, D9-THC, D8-
THC,
THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA,
CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND,
CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "THC" refers to tetrahydrocannabinol and has the
following structural
formula:
µH
,,-- `....,..
H 1
Within the context of this disclosure, compositions comprising THC are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "THCA" refers to tetrahydrocannabinolic acid and has
the
following structural formula:
-----......
OH 0
õ0=1.1
------....õ ,... -......
OH
H
I
/
Decarboxylating THCA with heat, light, etc., forms THC, D8-THC, D9-THC, and
other
potential cannabinoids. Within the context of this disclosure, compositions
comprising THCA are
formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "THCV" refers to tetrahydrocannabivarin and has the
following
structural formula:
-.....,.
OH
.011
=''''''
..,,, .........,...
H
1
0
=
26
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, compositions comprising THCV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "THCVA" refers to tetrahydrocannabivarinic acid and
has the following
structural formula:
sµk\01 L
OH
..---
0
/ --,0<---
Decarboxylating THCVA with heat, light, etc., forms THCV, D8-THCV, D9-THCV,
and
other possible cannabinoid derivatives. Within the context of this disclosure,
compositions
comprising THCVA are formulated with other compounds, thereby providing
previously
unavailable potency, control, consistency, purity, etc.
As used herein, the term "D8-THC" refers to delta-8-tetrahydrocannabinol and
has the
following structural formula:
ell'e. OH
i:
1
C tia _ ..........,:_ ,
CI%
Within the context of this disclosure, compositions comprising D8-THC are
formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "D8-THCV" refers to delta-84etrahydrocannabivarin and
has the
following structural formula:
CH1
------C.- OH
µ4".-..........õ-<'--..,,,
1:
I
aC-7..........., ,..., ,
27
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, compositions comprising D8-THCV are
formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "D9-THC" refers to delta-9-tetrahydrocannabinol and
has the
following structural formula:
CH,1
OH
'13
01;
Within the context of this disclosure, compositions comprising D9-THC are
formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "D9-THCV" refers to delta-94etrahydrocannabivarin and
has the
following structural formula:
C11.
OH
CHa ___________________________ I
/
Within the context of this disclosure, compositions comprising D9-THCV are
formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBD" refers to cannabidiol and has the following
structural
formula:
28
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
OH
N.....,,,,..-"" .e- -....,,...
,.,.. . .,."--,õ f= ,,,*''' .
Within the context of this disclosure, compositions comprising CBD are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBDA" refers to cannabidiolic acid and has the
following
structural formula:
OH 0
H
A
<
õ)::.....I.,,,,......... OH
H
.
k .
Decarboxylating CBDA with heat, light, etc., forms CBD and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBDA are formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBDV" refers to cannabidivarin and has the following
structural
formula:
--.....,õ
OH
" is.,
,-"e''''-= --^-"A
H
1
HO
Within the context of this disclosure, compositions comprising CBDV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
29
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "CBDVA" refers to cannabidivarinic acid and has the
following
structural formula:
OH 0
OH
HO
Decarboxylating CBDVA with heat, light, etc., forms CBDV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBDVA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBC" refers to cannabichromene and has the following
structural
formula:
HO
Within the context of this disclosure, compositions comprising CBC are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBCA" refers to cannabichromenic acid and has the
following
structural formula:
0 0
OH
Decarboxylating CBCA with heat, light, etc., forms CBC and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBCA are formulated
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBCV" refers to cannabichromevarin and has the
following
structural formula:
e-- N\O
HO
Within the context of this disclosure, compositions comprising CBCV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBCVA" refers to cannabichromevarinic acid and has
the
following structural formula:
0
4
OH
0
HO
Decarboxylating CBCVA with heat, light, etc., forms CBCV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBCVA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBG" refers to cannabigerol and has the following
structural
formula:
OH
31
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, compositions comprising CBG are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBGA" refers to cannabigerolic acid and has the
following
structural formula:
OH 0
= NN
OH
HO'
Decarboxylating CBGA with heat, light, etc., forms CBG and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBGA are formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBGV" refers to cannabigerovarin and has the
following
structural formula:
OH
Within the context of this disclosure, compositions comprising CBGV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBGVA" refers to cannabigerovarinic acid and has the
following
structural formula:
OH 0
OH
HO
Decarboxylating CBGVA with heat, light, etc., forms CBGV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBGVA
32
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBN" refers to cannabinol and has the following
structural
formula:
,--`--,
OH
1 [
1
¨
/ l s0
Within the context of this disclosure, compositions comprising CBN are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBNA" refers to cannabinolic acid and has the
following
structural formula:
".....,,...
OH 0
NNNN "r""NN`OH
I
N.
Decarboxylating CBNA with heat, light, etc., forms CBN and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBNA are formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBNV" or "CBV" refers to cannabivarin and has the
following
structural formula:
33
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
..----'7::---
-- ..,...s....,,,,
Oil
--="'-'1'
I,.....,..õ.......1,,,,,
......
....e.....'"...4 ,..,......,....,....,.,...
/
=
Within the context of this disclosure, compositions comprising CBNV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBNVA" refers to cannabivarinic acid and has the
following
structural formula:
OH 0
....
,
..,"" ..--"=-.N.
i .
Decarboxylating CBNVA with heat, light, etc., forms CBNV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBNVA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBND" refers to cannabinodiol and has the following
structural
formula:
.----
i
111111r--
lio .
Within the context of this disclosure, compositions comprising CBND are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
34
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "CBNDA" refers to cannabinodiolic acid and has the
following
structural formula:
OH 0
OH
HO
Decarboxylating CBNDA with heat, light, etc., forms CBND and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBNDA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBNDV" refers to cannabivarinodiol and has the
following
structural formula:
, I
HO
Within the context of this disclosure, compositions comprising CBNDV are
formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBNDVA" refers to cannabivarinodiolic acid and has
the
following structural formula:
911
11 H
0H
Ho
Decarboxylating CBNDVA with heat, light, etc., forms CBNDV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBNDVA
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBL" refers to cannabicyclol and has the following
structural
formula:
\ OH
.../Inh,õ..
I
1. a
H3C
Within the context of this disclosure, compositions comprising CBL are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBLA" refers to cannabicyclolic acid and has the
following
structural formula:
OH 0
--...õ
,
kb:4,4,
,
,
1-13C .
Decarboxylating CBLA with heat, light, etc., forms CBL and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBLA are formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBLV" refers to cannabicyclovarin and has the
following
structural formula:
OH
µ0's ..0
Hat;
=
36
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, compositions comprising CBLV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBLVA" refers to cannabielvarinsoinic acid and has
the
following structural formula:
OH 0
eitõoc., i =-'-'7',....,;:,.....ii.",..--.--
:
(\1/4O ,,Q ....w"' -\'-=,, : ..-;: -
N'',...
i-t.Q
Decarboxylating CBLVA with heat, light, etc., forms CBLV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBLVA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "CBE" refers to cannabielsoin and has the following
structural
formula:
OH
..¨'
/
I
H
\ HO
Within the context of this disclosure, compositions comprising CBE are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBEA" refers to cannabielsoic acid and has the
following
structural formula:
OH
0
CH:We,
N
.......,--k
37
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Decarboxylating CBEA with heat, light, etc., forms CBE and other possible
cannabinoid
derivatives. Within the context of this disclosure, compositions comprising
CBEA are formulated
with other compounds, thereby providing previously unavailable potency,
control, consistency,
purity, etc.
As used herein, the term "CBEV" refers to cannabivarinselsoin and has the
following
structural formula:
(.)H
H 0
11.4$0,.
H
He
Within the context of this disclosure, compositions comprising CBEV are
formulated with
other compounds, thereby providing previously unavailable potency, control,
consistency, purity,
etc.
As used herein, the term "CBEVA" refers to cannabivarinselsoinic acid and has
the
following structural formula:
OH
H
0 0
;
HO
Decarboxylating CBEVA with heat, light, etc., forms CBEV and other possible
cannabinoid derivatives. Within the context of this disclosure, compositions
comprising CBEVA
are formulated with other compounds, thereby providing previously unavailable
potency, control,
consistency, purity, etc.
As used herein, the term "terpene" refers to a compound built on an isoprenoid
structure or
produced by combining isoprene units, 5 carbon structures. Terpenes are also
associated with
producing smell in plants where terpenes are part of a class of secondary
compounds. In one
embodiment, the terpene is a hydrocarbon.
38
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, the term "terpene" does not necessarily
require 5
carbons or multiples of 5 carbons. It is understood that a reaction with
isoprene units does not
always result in a terpene comprising all the carbon atoms.
Within the context of this disclosure, the term "terpene" includes
Hemiterpenes,
Monoterpenols, Terpene esters, Diterpenes, Monoterpenes, Polyterpenes,
Tetraterpenes, Terpenoid
oxides, Sesterterpenes, Sesquiterpenes, Norisoprenoids, or their derivatives.
As well as isomeric,
enantiomeric, or optically active derivatives.
Derivatives of terpenes include terpenoids, hemiterpenoids, monoterpenoids,
sesquiterpenoids, sesterterpenoid, sesquarterpenoids,
tetraterpenoids, triterpenoids,
tetraterpenoids, polyterpenoids, isoprenoids, and steroids.
Within the context of this disclosure, the term terpene includes the a-
(alpha), 13- (beta), y-
(gamma), oxo-, isomers, or any combinations thereof.
Examples of terpenes within the context of this disclosure include: 7,8-
dihydro-alpha-
ionone, 7,8-dihydro-beta-ionone, Acetanisole, Acetic Acid, Acetyl Cedrene,
Anethole, Anisole,
Benzaldehyde, Bergamotene (Alpha-cis-Bergamotene) (Alpha-trans-Bergamotene),
Bisabolol
(Beta-Bisabolol), Alpha Bisabolol, Borneo', Bornyl Acetate, Butanoic/ Butyric
Acid, Cadinene
(Alpha-Cadinene) (Gamma-Cadinene), Cafestol, Caffeic acid, Camphene, Camphor,
Capsaicin,
Carene (Delta-3 -Carene), Carotene, Carvacrol, Dextro-Carvone, Laevo-Carvone,
Alpha-
Caryophyllene, Beta-Caryophyllene, Caryophyllene oxide, Cedrene (Alpha-
Cedrene) (Beta-
Cedrene), Cedrene Epoxide (Alpha-Cedrene Epoxide), Cedrol, Cembrene,
Chlorogenic Acid,
Cinnamaldehyde, Alpha-amyl-Cinnamaldehyde, Alpha-hexyl-Cinnamaldehyde,
Cinnamic Acid,
Cinnamyl Alcohol, Citronellal, Citronellol, Cryptone, Curcumene (Alpha-
Curcumene) (Gamma-
Curcumene), Decanal, Dehydrovomifoliol, Dially1 Disulfide,
Dihydroactinidiolide, Dimethyl
Disulfide, Eicosane/Icosane, Elemene (Beta-Elemene), Estragole, Ethyl acetate,
Ethyl Cinnamate,
Ethyl maltol, Eucalypto1/1,8-Cineole, Eudesmol (Alpha-Eudesmol) (Beta-
Eudesmol) (Gamma-
Eudesmol), Eugenol, Euphol, Farnesene, Farnesol, Fenchol (Beta-Fenchol),
Fenchone, Geraniol,
Geranyl acetate, Germacrenes, Germacrene B, Guaia-1(10),11-diene, Guaiacol,
Guaiene (Alpha-
Guaiene), Gurjunene (Alpha-Gurjunene), Herniarin, Hexanaldehyde, Hexanoic
Acid, Humulene
(Alpha-Humulene) (Beta-Humulene), Ionol (3-oxo-alpha-ionol) (Beta-Ionol),
Ionone (Alpha-
Ionone) (Beta-Ionone), Ipsdienol, Isoamyl Acetate, Isoamyl Alcohol, Isoamyl
Formate, Isoborneol,
Isomyrcenol, Isopulegol, Isovaleric Acid, Isoprene, Kahweol, Lavandulol,
Limonene, Gamma-
Linolenic Acid, Linalool, Longifolene, Alpha-Longipinene, Lycopene, Menthol,
Methyl butyrate,
3 -Mercapto-2-Methylpentanal, Mercaptan/Thiols, Beta-Mercaptoethanol,
Mercaptoacetic Acid,
Ally' Mercaptan, Benzyl Mercaptan, Butyl Mercaptan, Ethyl Mercaptan, Methyl
Mercaptan,
Furfuryl Mercaptan, Ethylene Mercaptan, Propyl Mercaptan, Thenyl Mercaptan,
Methyl
Salicylate, Methylbutenol, Methyl-2-Methylvalerate, Methyl Thiobutyrate,
Myrcene (Beta-
39
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Myrcene), Gamma-Muurolene, Nepetalactone, Nero!, Nerolidol, Neryl acetate,
Nonanaldehyde,
Nonanoic Acid, Ocimene, Octanal, Octanoic Acid, P-Cymene, Pentyl butyrate,
Phellandrene,
Phenylacetaldehyde, Phenylethanethiol, Phenylacetic Acid, Phytol, Pinene, Beta-
Pinene,
Propanethiol, Pristimerin, Pulegone, Quercetin, Retinol, Rutin, Sabinene,
Sabinene Hydrate, cis-
Sabinene Hydrate, trans-Sabinene Hydrate, Safranal, Alpha-Selinene, Alpha-
Sinensal, Beta-
Sinensal, Beta-Sitosterol, Squalene, Taxadiene, Terpin hydrate, Terpineol,
Terpine-4-o!, Alpha-
Terpinene, Gamma-Terpinene, Terpinolene, Thiophenol, Thuj one, Thymol, Alpha-
Tocopherol,
Tonka Undecanone, Undecanal, Valeraldehyde/Pentanal, Verdoxan, Alpha-Ylangene,
Umbelliferone, or Vanillin.
As used herein, the term "7,8-dihydro-alpha-ionone" refers to a compound with
the
following structural formula:
0
7,8-dihydro-alpha-ionone is often characterized as having a woody, floral
odor.
As used herein, the term "7,8-dihydro-beta-ionone" refers to a compound with
the
following structural formula:
0
7,8-dihydro-beta-ionone is often characterized as having a woody aroma.
As used herein, the term "acetanisole" refers to a compound with the following
structural
formula:
0
CH3
H3
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Acetanisole is often characterized as having a sweet, anisic, vanilla-like
aroma with powdery,
balsamic, and benzaldehyde nuances. Acetanisole is also used as a flavoring
agent.
As used herein, the term "acetic acid" refers to a compound with the following
structural
formula:
0
OH
Acetic acid is often characterized as a one of the main constituents of
vinegar.
As used herein, the term "acetyl cedrene" refers to a compound with the
following
structural formula:
SH
0
Acetyl cedrene is often characterized as having a warm, woody, amber musky
aroma. Acetyl
cedrene is also a fragrance agent.
As used herein, the term "anethole" refers to an aromatic compound having the
following
structural formula:
OC H3
Anethole is often characterized as having a sweet, anise, licorice aroma.
Anethole is used in a wide
variety of fragrances and flavors.
As used herein, the term "anisole" refers to a compound with the following
structural
formula:
41
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
/C1-43
0
...-='''''
--..õ,...õ
1
Anisole is often characterized as smelling like anise seeds.
As used herein, the term "benzaldehyde" refers to a compound with the
following structural
formula:
0 ..õ....--H
Benzaldehyde is often characterized as haying an almond-like odor.
As used herein, the term "bergamotene" refers to a compound including either
or both of
alpha-cis-bergamotene and/or alpha-trans-Bergamotene in a pure and/or mixture
of any ratio.
Alpha-cis-bergamotene refers to a compound with the following structural
formula:
.....- ,,
=,.......õ
--"---"zz----õ---= -...;,-.....,--'
Alpha-cis-bergamotene is often characterized as haying a strong odor of ground
black
pepper. Alpha-cis-bergamotene is an aroma component of many species of the
family orchidaceae.
Alpha-trans-Bergamotene refers to the following structural formula:
I
, =-.,, ....,, -"---",õ,,,....,,,P"
-:-,---= --'
-...---
Alpha-trans-Bergamotene is often characterized as haying a medium strength,
warm, tea-
leaf-like odor. Alpha-trans-Bergamotene is used in the chemical communication
system of some
species of aphids.
42
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "bisabolol" refers to a compound including either or
both of alpha
bisabolol and/or beta bisabolol in a pure and/or mixture of any ratio.
Alpha-bisabolol refers to a compound with the following structural formula:
õ.. j.,..:õ...õ,...õ Is
----=,:ists, H
Alpha-bisabolol is often characterized as the active component of chamomile.
Beta-bisabolol refers to a compound with the following structural formula:
I
.....,õ..
OH
Beta-bisabolol is often characterized as having a citrus, floral, lemon,
sweet, herbaceous aroma.
As used herein, the term "borneol" refers to a compound having the following
structural
formula:
H
----'
,
OH
Borneo' is often characterized as having a menthol aroma, similar to camphor.
Borneo' can
also be converted into camphor.
As used herein, the term "bornyl acetate" refers to a compound with the
following structural
formula:
43
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
\\L .....õ...õ.õ.7µ
t)
> 0
Bornyl acetate is often characterized as having a pine, camphoraceous, herbal,
and balsamic odor.
As used herein, "butanoic/butyric acid" refers to a compound with the
following structural
formula:
0
OH
Butyric acid is often characterized as having an unpleasant, acrid odor
normally found in
perspiration, flatulence, and rancid butter.
As used herein, the term "cadinene" refers to a compound including either or
both of alpha-
cadinene and/or gamma-cadinene in a pure and/or mixture of any ratio.
Alpha-cadinene refers to a compound with the following structural formula:
--Y i
õ-
H
Alpha-cadinene is often characterized as having a pungent, smoky, woody,
guaiac wood-like odor.
Gamma-cadinene refers to a compound having either of the following structural
formula:
,
;
ti H 1
c...,...._ ..,....
..,õ .,
ts. ,
A I
H Ft ii
11
=
or .
44
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Gamma-cadinene is often characterized as having an herbaceous, herbal, woody
aroma. Gamma-
cadinene has shown some antimicrobial and antibacterial properties. Many
species of termites and
a few beetles utilize gamma-cadinene in their chemical communication systems.
As used herein, the term "cafestol" refers to a compound with the following
structural
formula:
Hz: VC)
1 I
."''''''Jr-*" --------------'
H '
Ro mi.,
-s-'`'=O's'''
ON
Cafestol is often characterized as major constituent in coffee.
As used herein, the term "caffeic acid" refers to a compound with the
following structural
formula:
0
11
HO ,.........., .",
OH
HO' .
Caffeic acid is often characterized as a key intermediate in the synthesis of
lignin.
As used herein, the term "camphene" refers to a compound with the following
structural
formula:
Camphene is often characterized as having a pungent, herbal, fir needle smell.
Camphene is used
in fragrances and food additives. Camphene is a minor constituent of many
essential oils such as
turpentine, cypress oil, camphor oil, citronella oil, neroli, ginger oil, and
valerian.
As used herein, the term "camphor" refers to a compound with either of the
following
structural formulas:
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
-- ---..---
--
,,-- -
i
'1....------1
\
o or 0 .
Within the context of this disclosure, the term "camphor" includes enantiomers
as either a single
form or a mixture in any ratio. Camphor has a very characteristic odor for
which the tree is named.
Camphor is used as a flavor and fragrance agent in chewing gum, hard candy,
etc.
As used herein, the term "capsaicin" refers to a chemical compound with
following
structural formula:
1-10,
-N,
'N's,,Q. = :V . ' NN.
1
0
Capsaicin is often odorless. Capsaicin is often characterized as an irritant
for mammals, known for
the sensation it provokes when inhaled, eaten, or applied to the skin.
As used herein, the term "carene" or "delta-3-carene" refers to a compound
with the
following structural formula:
IISIIIIIIIIIIP' ...:.'t.
,.
Delta-3-carene, sometimes referred to as "Carene", is often characterized as
having a sweet and
pungent odor.
As used herein, the term "carotene" refers to any one of a series of related
compounds
having the chemical formula C4oHx.
Within the context of this disclosure, the term "carotene" refers to any of
the isomeric forms
of carotene in a pure and/or mixture in any ratio. Carotene is often
characterized as an important
compound in the photosynthesis process.
As used herein, term "carvacrol" refers to a compound with the following
structural
formula:
46
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
,.OH
1
Carvacrol is often characterized as having a pungent odor of oregano.
Carvacrol is often used as a
flavor and fragrance agent and its flavor has been described as spicy, herbal,
phenolic, medicinal,
and woody.
As used herein, the term "dextro-carvone" refers to the S-(+) enantiomer of
carvone with
the following structural formula:
t.""----j-
õ-..-..-..-..-..-..-..-..-..-..-..-..-..=
/ .
Dextro-carvone is often characterized as having a spicy, bready, caraway
aroma. Dextro-carvone
is found in mandarin peel oil and gingergrass oil. Dextro-carvone is the
principal constituent of the
oil from caraway seeds.
As used herein, the term "laevo-carvone" refers to the R-(-) enantiomer of
carvone with the
following structural formula:
0
=----.õ.õ
--
---
,
õ
Laevo-carvone is often characterized as having a sweet, minty, herbaceous,
spearmint odor. Laevo-
carvone is found in spearmint and kuromoji oils.
As used herein, the term "beta-caryophyllene" refers to a compound with the
following
structural formula:
47
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Beta-Caryophyllene is often characterized as a flavor component of black
pepper. Beta-
caryophyllene is often referred to as caryophyllene.
As used herein, the term "caryophyllene oxide" refers a compound with the
following
structural formula:
t,t
Caryophyllene oxide is often characterized as having a lemon balm odor.
As used herein, the term "cedrene" refers to either or both of alpha-cedrene
and/or beta-
Cedrene as pure forms or mixtures in any ratio.
Alpha-cedrene refers to a compound having the following structural formula:
CH3 CH3
CH3
-.smICH3
Alpha-cedrene is often characterized as having a medium strength, woody,
sweet, fresh aroma of
cedar. Alpha-cedrene is used in bakery items, sherbet and sorbet. Alpha-
cedrene is a major
component in the essential oil of cedar.
Beta-cedrene refers to a compound with the following structural formula:
48
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
il
CH3
F I ",,,,,, = , 31* ttti I
L.,..," ''''.=:.-.1,.
Beta-cedrene is often characterized as having a woody aroma of cedar. Beta-
cedrene is a major
component in the essential oil of cedar.
As used herein, the term "cedrene epoxide" or "alpha-cedrene epoxide" refers
to a
compound with the following structural formula:
..-(--)
- ,,..-----'
Alpha-cedrene epoxide is often characterized as having a woody, amber,
tobacco, sandalwood, and
fresh patchouli aroma. Alpha-cedrene epoxide is commonly used as a fragrance
agent and a
perfuming agent for cosmetics.
As used herein, the term "cedrol" refers to a compound with the following
structural
formula:
,
..
...
,.=
'Is
14
i
Cedrol is often characterized as having a very faint aroma that is sweet,
cedar, and woody. Cedrol
is a major component of cedar wood oil.
As used herein, the term "cembrene A" refers to a compound with the following
structural
formula:
,
1
___________________________________ \
/
49
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Cembrene A is often characterized as having a faint wax like odor.
As used herein, the term "chlorogenic acid" refers to a compound with the
following
structural formula:
oil
1., 0004
C.,.1.... 0
<
. E)-- =---....' f s."--,
1 I
OM
ON .
Chlorogenic acid can often be found in peaches, prunes, and green coffee bean
extract.
As used herein, the term "cinnamaldehyde" refers to a compound with the
following
structural formula:
P
..,..--- õ,,..õ._ ====õ.---1--
--'14
1
Cinnamaldehyde is often characterized as having a spicy, sweet cinnamon odor,
and gives
cinnamon its flavor. Cinnamaldehyde occurs naturally in the bark of cinnamon
trees and other
species of the genus Cinnamomum.
As used herein, the term "alpha-hexyl-cinnamaldehyde" refers to a compound
with the
following structural formula:
a
H
Alpha-hexyl-cinnamaldehyde is often characterized as having a sweet, floral,
green, jasmine, citrus,
and fruity aroma with powdery, tropical or spicy notes.
As used herein, the term "alpha-amyl-cinnamaldehyde" refers to a compound with
the
following structural formula:
0
H
I
'''''...õ...,..;,.='''''''' CH2(CH2 }3CH3
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Alpha-amyl-cinnamaldehyde is often characterized as having a sweet, floral,
fruity, herbal,
jasmine, and tropical aroma.
As used herein, the term "cinnamic acid" refers to a compound with the
following structural
formula:
0
1
c
Cinnamic acid is often characterized as having a balsamic, sweet, storax,
honey-like odor.
Cinnamic acid is obtained from the oil of cinnamon or from balsams such as
storax.
As used herein, the term "cinnamyl alcohol" refers to a compound with the
following
structural formula:
1
C.-
Cinnamyl alcohol is often characterized as having a cinnamon spice, floral
green, and fermented
odor with powdery balsamic nuances. As a flavor component cinnamyl alcohol has
a green, floral,
spicy, and honey flavor with a fermented yeasty nuance.
As used herein, the term "citronellal" refers to a compound with the following
structural
formula:
'0
Citronellal is often characterized as making up to 80% of the leaf oil from
Kaffir lime leaves and
as the characteristic aroma.
As used herein, the term "citronellol" refers to either or both of the (+) and
(-) enantiomers
as pure forms or mixtures in any ratio.
The (+) enantiomer has the following structural formula:
j.,
--....1
,.,., 1..õ..õ.
"-`01-4
I
Cti3"*"..---CH3
=
51
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
The (-) form has the following structural formula:
CH:s
,..-----1------...
..'
.-----' ..----
HO'''' ,----'
I
..,"-----. 113C
1-istC
Citronellol is often characterized as having a floral, rosy, sweet, citrus
with green, fatty, terpene-
nuanced odor.
As used herein, the term "cryptone" refers to a compound with the following
structural
formula:
NN? < \\Ns 0
Cryptone is often characterized as having a woody minty herbaceous smell.
As used herein, the term "curcumene" refers either or both alpha-curcumene
and/or
gamma-curcumene as pure forms or mixtures in any ratio.
Alpha-curcumene has the following structural formula:
-------
i-i
-------------
I
Alpha-curcumene is often characterized as having an odor similar to turmeric.
Alpha-curcumene is
found prominently in the Zingiber genus of ginger.
Gamma-curcumene has the following structural formula:
?
40 ,õ.....
52
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Gamma-curcumene is often characterized as having an earthy aroma. Gamma-
curcumene is found
prominently in the Libocedrus bidwillii tree.
As used herein, the term "decanal" refers to a compound with the following
structural
formula:
o
õ...,......---,-,..,,,,,,.....-----,.....õ.õ
Decanal is often characterized as having a citrus odor. Decanal is used as a
fragrance and flavoring
agent.
As used herein, the term "dehydrovomifoliol" refers to a compound with the
following
structural formula:
g
...-
0 õ....:
Dehydrovomifoliol is often characterized as having a fruity and flowery odor.
As used herein, the term "diallyl disulfide" refers to a compound with the
following
structural formula:
.-:5-
.,---- S
Dially1 disulfide is often characterized as having a strong, alliaceous,
onion, and garlic-like odor.
As used herein, the term "dihydroactinidiolide" refers to a compound with the
following
structural formula:
-Y
0
Dihydroactinidiolide is often characterized as having a fruity, musky,
coumarin tea-like, peach
aroma.
As used herein, the term "dimethyl disulfide" refers to a compound with the
following
structural formula:
S
Dimethyl disulfide is often characterized as having a sulfurous, rotten aroma.
53
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "eicosane" or "icosane" refers to a compound with the
chemical
formula C201-142 and haying 366,619 constitutional isomers with the following
skeletal structure:
Eicosane is often characterized as haying a waxy odor. Eicosane is used in
fragrance concentrates.
As used herein, the term "beta-elemene" refers to a compound with the
following structural
formula:
i...Iõ
1
---..- .
Beta-elemene is often characterized as haying a sweet aroma.
As used herein, the term "estragole" refers to a compound with the following
structural
formula:
I
Estragole is an isomer of anethole. Estragole is often characterized as haying
an anise seed smell
and occurs in tarragon oil, turpentine, and other essential oils.
As used herein, the term "ethyl acetate" refers to a compound with the
following structural
formula:
0
------IL-0,--,
Ethyl acetate is often characterized as haying an acidic, fruity, dirty,
cheesy, fermented odor.
As used herein, the term "ethyl cinnamate" refers to a compound with the
following
structural formula:
o
0
1
54
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Ethyl Cinnamate is often characterized as having a sweet, balsamic, spicy,
fruity, berry, and plum
odor.
As used herein, the term "ethyl maltol" refers to a compound with the
following structural
formula:
1 CH3
Ethyl maltol is often characterized as having a sweet smell similar to
caramelized sugar and cooked
fruit.
As used herein, the term "eucalyptol" refers to a terpene with the following
structural
formula:
0
Eucalyptol is often characterized as having a mint-like smell. Eucalyptol is
also known by 1,8-
cineol, 1,8-cineole, cajeputol, 1,8-epoxy-p-menthane, 1,8-oxido-p-menthane,
eucalyptol,
eucalyptole, 1,3,3-trimethy1-2-oxabicyclo[2,2,2]octane, cineol, and cineole.
As used herein, the term "eudesmol" refers to alpha-eudesmol, beta-eudesmol,
or gamma-
eudesmol as pure forms or mixtures in any ratio.
Alpha-eudesmol has the following structural formula:
0
/
=
Alpha-eudesmol is often characterized as having a sweet, woody odor.
Beta-eudesmol has the following structural formula:
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
. Is ll
1 =
---)
Beta-eudesmol is often characterized as having a sweet, green, woody, yuzu-
like aroma.
Gamma-eudesmol has the following structural formula:
HI' 40
Gamma-eudesmol is often characterized as having a waxy, sweet, woody, floral
odor.
As used herein the term "eugenol" refers to a compound with the following
structural
formula:
0
1
e.,...-. -,... HCY'''
Eugenol is often characterized as causing the aromatic smell of cloves.
Eugenol is found in insect
attractants as well as UV absorbers.
As used herein, the term "euphol" refers to a compound with the following
structural
formula:
....y.
4... i
,
,C_¨õ,i...,....4...,}-2
,....,
1
,
...--
--s"011"-
Euphol is often characterized as the main constituent in the sap of Euphorbia
tirucalli.
As used herein, the term "farnesene" refers to six closely related compounds.
(E, E)-alphafarnesene is one of these six molecules and has the following
structural formula:
;
56
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, the term "farnesene" refers to any one
of the six
closely related compounds, either alone or in combination of any other of
those six closely related
compounds. Farnesene is often characterized as having a fragrance of magnolia
flowers and has
citrus notes with green, woody, vegetative odor with hints of lavender.
As used herein, the term "farnesol" refers to a compound with the following
structural
formula:
=
Farnesol is often characterized as having a mild, fresh, sweet, floral, linden
tree odor. Farnesol is
used in cosmetics, flavors and fragrances.
As used herein, the term "fenchol" or "beta-fenchol" refers to a compound with
the
following structural formula:
CH3
OH
CH3
Beta-fenchol is often characterized as having a camphorous, piney, woody, dry,
sweet, lemon scent.
Beta-fenchol is used as a flavor and fragrance agent.
As used herein, the term "fenchone" refers to a compound with the following
structural
formula:
/
Fenchone is often characterized as having a camphorous, thuja, cedar leaf,
herbal, earthy, woody
aroma.
As used herein, the term "geraniol" refers to a compound of the following
structural
formula:
Geraniol is often characterized as having a sweet-rose like scent.
57
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "geranyl acetate" refers to a compound with the
following
structural formula:
. 0
i
:
:
Q .
Geranyl acetate is often characterized as having a floral and fruit aroma.
Geranyl acetate is
found in a variety of natural oils from plants such as citronella, lemon
grass, sassafras, rose, and
many others.
As used herein, the term "geranylfarnesol" refers to a compound with the
following
structural formula:
H H H H
N, PH
,
1 i .
Geranylfarnesol is often characterized as a clear colorless liquid.
As used herein, the term "germacrene" refers to a class of hydrocarbons.
Within the context
of this disclosure, the term "germacrene" refers to any of the five isomers as
either pure forms or
in any combination of the five isomers.
Germacrene A refers to the following structural formula:
j---..----
, .---
--4,õ..,
Germacrene B refers to the following structural formula:
______________________________ ¨7----
--..1i.-.H.
Germacrene C refers to the following structural formula:
58
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
---1
,..--.----:"---,N,,
..,.. j---
,,,- --....,
Germacrene D refers to the following structural formula:
i
Germacrene E refers to the following structural formula:
....
As used herein, the term "guaia-1(10), 11-diene" refers to a compound with the
following
structural formula:
ii
Guaia-1(10),11-diene is often characterized as having a sweet, woody aroma.
Guaia-1(10),11-diene
is used as a fragrance for a wide range of products from food additives,
tobacco flavorings and
general cosmetics, to odorizing rooms.
As used herein, the term "guaiacol" refers to a compound with the following
structural
formula:
59
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
OCKa
OH
Guaiacol is often characterized as having a smoke-like, spicy, woody,
medicinal odor. Guaiacol
has a sweet, powdery, musty, vanilla, floral, almond flavor.
As used herein, the term "alpha-guaiene" refers to a compound with the
following structural
formula:
Alpha-guaiene is often characterized as having a sweet, earthy, woody,
balsamic, peppery aroma.
As used herein, the term "gurjunene" or "alpha-gurjunene" refers to a compound
with the
following structural formula:
0-13
H "3:
ais
cH3
043
Alpha-gurjunene is often characterized as having a woody, balsamic odor. Alpha-
gurjunene is used
in cosmetics and fragrances.
As used herein, the term "herniarin" refers to a compound with the following
structural
formula:
0 0 0
cH3
Herniarin is often found in Herniaria glabra, Ayanpana triplinervis, and in
species of the genus
Prunus (P. mahaleb, P. pensylvanica, and P. maximowiczil).
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "hexanaldehyde" refers to a compound with the
following
structural formula:
Hexanaldehyde is often characterized as having a grassy odor. Hexanaldehyde is
also called
hexanal.
As used herein, the term "hexanoic acid" refers to a compound with the
following structural
formula:
0
011
Hexanoic acid is often characterized as having a pungent, acrid, sour, fatty,
sweaty, rancid cheese
odor.
As used herein, the term "alpha-humulene" refers to a compound with the
following
structural formula:
--------,---- --
4.'",,,
,./1_,./......\
Alpha-humulene is often characterized as contributing to the flavor profile of
beer. Alpha-
humulene is sometimes often referred to as simply "Humulene" or
"Caryophyllene" and in the
context of this disclosure both may be used interchangeably.
As used herein, the term "beta-humulene" refers to a compound with the
following
structural formula:
CH,
ot-13
.S.._.
\\0,
I
L
o43
* '''---j::'s\--
Beta-humulene is often characterized as having a green aroma.
As used herein, the term "ionol" refers to a compound with the following
structural
formula:
61
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
OH
Ionol is also known as Butylated Hydroxy Toluene (BHT). For the purpose of
this disclosure
"ionol" also refers to 3-oxo-alpha-ionol and/or beta-ionol in a pure and/or
mixture of any ratio.
Ionol is often characterized as having a sweet, woody, herbal, fruity, floral,
tropical, and berry
aroma.
As used herein, the term "ionone" refers to either or both alpha-ionone and/or
beta-ionone
as pure forms or mixtures in any ratio.
Alpha-ionone refers to the following structural formula:
c.)
Beta-ionone refers to the following structural formula:
0
Alpha-ionone and beta-ionone as a mixture have an aroma similar to the violet
flower.
As used herein, the term "ipsdienol" refers to a compound with the following
structural
formula:
OH
Ipsdienol is often characterized as having a balsamic, piney aroma.
As used herein, the term "isoamyl acetate" refers to a compound with the
following
structural formula:
0
Isoamyl acetate is often characterized as having an odor similar to banana and
pears.
62
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "isoamyl alcohol" refers to a compound with the
following
structural formula:
Isoamyl alcohol is often characterized as having a pungent, fermented, fusel,
alcohol-like, aroma
with fruity, banana and molasses notes. Isoamyl alcohol is used as a flavor
and fragrance agent.
As used herein, the term "isoamyl formate" refers to a compound with the
following
structural formula:
0 CH3
H "IN.0 CH3
Isoamyl formate is often characterized as having a vinous, dry, earthy,
fruity, green, plum, and
blackcurrant aroma.
As used herein, the term "isoborneol" refers to a compound with the following
structural
formula:
cIii
OH
Isoborneol is often characterized as having a camphoraceous, sweet & musty
aroma.
As used herein, the term "isomyrcenol" refers to a compound with the following
structural
formula:
OH
Isomyrcenol is often characterized as having a fresh, floral, lime-like odor.
Isomyrcenol is used in
the chemical communication systems of beetles.
As used herein, the term "isopulegol" refers to a compound with the following
structural
formula:
63
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
HO,
-
Isopulegol is often characterized as having a medium strength odor that is
minty, cooling and
bittersweet. Within the context of this disclosure, "isopulegol" may also
refer to any number of
isomeric forms.
As used herein, the term "isovaleric acid" refers to a compound with the
following
structural formula:
I....õ.:\,,,
Isovaleric acid is often characterized as having a strong, pungent, sour, and
sweaty cheese smell.
Isovaleric acid is also known as 3-methylbutanoic acid.
As used herein, the term "isoprene" refers to a compound with the following
structural
formula:
CH3 CH2
\ /7
C ------ C
\
CH2 H
Isoprene is often considered as a building block for many other terpenes.
As used herein, the term "kahweol" refers to a compound with the following
structural
formula:
50-"-----.õ .....--- ----,
t.1 Li
1- I '
T.-- "--,.....L.--
ti
====., . ;; ,'"--
".-........õ,,,,,-*
OH .
As used herein, the term "lavandulol" refers to either the R and S enantiomers
as pure forms
or mixture in any ratio with the following structural formula:
64
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
........----...-------=-=õ.õ------,õ
---' OH .
Lavandulol is often found in the essential oil of lavender.
As used herein, the term "limonene" refers to a terpene with the following
structural
formula:
H ---:
Limonene is often characterized as having a smell similar to oranges and other
citrus fruits. Within
the context of this disclosure, the term "Limonene" encompasses all possible
enantiomers and
isomers of the compound in as either individual compounds or in a racemic
mixture.
As used herein, the term "gamma-linolenic acid" refers to a compound with the
following
structural formula:
0
HO .
Gamma-linolenic acid is often characterized as an unsaturated fatty acid found
primarily in
vegetable oils.
As used herein, the term "linalool" refers to a terpene with the following
structural formula:
1-40\ i
Linalool has two known enantiomeric forms. (S)-(+)-Linalool is often
characterized as sweet and
floral and the (R)-form is more woody and lavender-like. Within the context of
this disclosure, the
"Linalool" refers to either of the enantiomers or a racemic mixture of the
two.
As used herein, the term "longifolene" refers to a compound having both (+)
and (-)
enantiomers. The (+) enantiomer refers to the following structural formula:
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this disclosure, the term "longifolene" refers to either
of its (+) and/or (-)
enantiomers in a pure form or mixture in any ratio. Longifolene is often
characterized as having a
sweet, woody, rosy, medical, fir needle odor.
As used herein, the term "alpha-longipinene" refers to a compound with the
following
structural formula:
Alpha-longipinene is often characterized as having a pine aroma.
As used herein, the term "lycopene" refers to a compound with the following
structural
formula:
Lycopene is often characterized for its red color.
As used herein, the term "luteolin" refers to a compound with the structural
formula:
0
Luteolin is often found in leaves, rinds, barks, clover blossoms, and ragweed
pollen.
As used herein, the term "menthol" refers to a compound with the following
structural
formula:
:pn.3
CHa OH
66
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Menthol is often characterized as having a cooling, minty, peppermint aroma
and flavor. Menthol
is obtained from cornmint, peppermint or other mint oils.
As used herein, the term "methyl butyrate" refers to a compound with the
following
structural formula:
a
--Ii
0
Methyl butyrate is often characterized as having a sulfurous odor.
As used herein, the term "3-Mercapto-2-Methylpentanal" refers to a compound
with the
following structural formula:
H
14 "e"-- .----`---'---
H
.----'' H
..,----
3-Mercapto-2-Methylpentanal is often characterized as having a sulfurous,
alliaceous, garlic odor.
As used herein, the term "3-Mercapto-2-Methylpentanol" refers to a compound
with the
following structural formula:
01-13
SH
3-Mercapto-2-Methylpentanol is often characterized as having a very strong,
sulfurous, onion type
aroma.
As used herein, the term "mercaptan" refers to an organosulfur compound
containing a
carbon-bonded sulfhydryl. Mercaptan is often characterized as the main odor
constituent added to
assist in the detection of natural gas (which in pure form is odorless), and
the "smell of natural gas"
is due to the smell of the mercaptan thiol used as the odorant. Mercaptan is
also referred to as thiol.
As used herein, the term "beta-mercaptoethanol" refers to a compound with the
following
structural formula:
SH
Beta-mercaptoethanol is often characterized as having an extremely strong and
persistent aroma of
sulfur.
67
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "mercaptoacetic acid" refers to a compound with the
following
structural formula:
0
OH
Mercaptoacetic acid is often characterized as having an ugly, sharp, acrid,
skunk smell with plenty
of endurance. Mercaptoacetic acid is also referred to as thioglycolic acid.
As used herein, the term "ally' mercaptan" refers to a compound with the
following
structural formula:
SH
Ally' mercaptan is often characterized as having a strong sulfurous and
alliaceous aroma.
As used herein, the term "benzyl mercaptan" refers to a compound with the
following
structural formula:
sH
Benzyl mercaptan is often characterized as having a strong, sharp, alliaceous,
sulfurous, onion,
garlic, and horseradish aroma.
As used herein, the term "butyl mercaptan" refers to a compound with the
following
chemical formula C4H10S. In one embodiment, the butyl mercaptan has the
following structural
formula:
CHSH
In one embodiment, the butyl mercaptan has the following structural formula:
SH
CH3
cH3
Butyl mercaptan is often characterized as having an extremely strong foul-
smelling odor,
commonly described as "skunk" odor.
As used herein, the term "methyl mercaptan" refers to a compound with the
following
structural formula:
68
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Hi,.
õõ.. ______________________________
-s
Methyl mercaptan is often characterized as having an extremely strong,
sulfurous, decomposing
cabbage, skunky aroma. Methyl mercaptan is also called methanethiol.
As used herein, the term "furfuryl mercaptan" refers to a compound with the
following
structural formula:
0
SH
Furfuryl mercaptan is often characterized as having a very strong, oily,
fatty, sulfurous, skunky
odor.
As used herein, the term "ethylene mercaptan" refers to a compound with the
following
structural formula:
H S SH
Ethylene mercaptan is often characterized as having a very high strength,
sulfurous, skunky odor.
As used herein, the term "propyl mercaptan" refers to a compound with the
following
structural formula:
Propyl mercaptan is often characterized as having a high strength, alliaceous,
natural gas, sweet
onion, cabbage odor. Propyl mercaptan is also referred to as propanethiol.
As used herein, the term "thenyl mercaptan" refers to a compound with the
following
structural formula:
SH
'7
Thenyl mercaptan is often characterized as having a strong roast coffee, fishy
aroma. Thenyl
mercaptan is used as a flavoring agent mimicking the flavor of coffee.
As used herein, the term "methyl salicylate" refers to a compound with the
following
structural formula:
69
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
0
0
I
ON .
Methyl salicylate is often characterized as having a strong, distinct
wintergreen aroma. Methyl
salicylate is used as a fragrance agent, a food and beverage agent.
As used herein, the term "methylbutenol" refers to a compound with the
following
structural formula:
HO CH3 '
CH3 .
Methylbutenol is often characterized as having a very strong, malty herb
aroma. Methylbutenol is
released in high concentrations from lodgepole pine trees.
As used herein, the term "methyl-2-methylvalerate" refers to a carboxylic acid
with the
following structural formula:
0
i
Methyl-2-methylvalerate is often characterized as having a fruity, sweet,
berry, pineapple, apple,
banana, green melon, and tropical aromas.
As used herein, the term "methyl thiobutyrate" refers to a compound with the
following
structural formula:
0
H.1 SCII;
Methyl thiobutyrate is often characterized as a flavoring and food agent.
As used herein, the term "beta-myrcene" refers to a terpene with the following
structural
formula:
....õ.....õ...".",,,,,,
Beta-Myrcene is often characterized as having an earthy, fruity clove-like
odor. Beta-myrcene is
also referred to as "myrcene".
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "gamma-muurolene" refers to a compound with the
following
structural formula:
---- V
...-----
E.
Gamma-muurolene is often characterized as having an herbal, woody, and spicy
aroma.
As used herein, the term "nepetalactone" refers to a compound with the
following structural
formula:
0
0
Nepetalactone is often characterized as having a valerian odor. Nepetalactone
is also one of the
main attractants and stimulants in catnip, which, when inhaled, insights wild
play behavior in many
cats.
As used herein, the term "nerol" refers to a compound with the following
structural
formula:
OH
Nerol is often characterized a constituent of fragrances in cosmetics and as a
flavor agent.
As used herein, the term "nerolidol" refers to a compound with either of the
following
structural formulas or any mixture thereby:
HO, /
or
HQ
=
71
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Nerolidol is often characterized as having a woody aroma, similar to fresh
bark. Within the context
of this disclosure, the term "Nerolidol" refers to either or both of the cis
and trans isomers.
As used herein, the term "neryl acetate" refers to a compound with the
following structural
formula:
1.
Neryl acetate is often characterized as having a floral and fruity aroma.
As used herein, the term "nonanaldehyde" refers to a compound with the
following
structural formula:
Nonanaldehyde is often characterized as having a soapy, citrus odor.
Nonanaldehyde is a
component of perfumes, although it also occurs in several natural oils.
Nonanaldehyde is also
referred to as nonanal.
As used herein, the term "nonanoic acid" refers to a carboxylic acid with the
following
structural formula:
9
Nonanoic acid is often characterized as having an unpleasant, rancid, waxy,
dirty, and cheesy
aroma.
As used herein, the term "ocimene" refers to a compound with one of the
isomeric forms:
Within the context of this disclosure, ocimene refers to any of the isomers in
a single pure form or
a mixture in any ratio.
As used herein, the term "octanal" refers to a compound with the following
structural
formula:
o.
Octanal is often characterized as having a very strong waxy, citrus, orange
peel aroma.
72
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "octanoic acid" refers to a compound with the
following structural
formula:
Octanoic acid is often characterized as having a musty, rancid, cheesy, sweat-
like odor Octanoic
acid is used as a cosmetic surfactant and as a flavoring agent for processed
cheeses. Octanoic acid
is also referred to as caprylic acid.
As used herein, the term "p-cymene" refers to a compound with the following
structural
formula:
CH 3 ,C1-13
CH3
Within context of this disclosure, Cymene may refer to p-Cymene or any other
isomeric
form, e.g., m-Cymene or o-Cymene.
As used herein, the term "pentyl butyrate" refers to a compound with the
following
structural formula:
0
0
Pentyl butyrate is often characterized as having a smell reminiscent of pear
or apricot.
As used herein, the term "phellandrene" refers to either of the two structural
formulas:
--- (alpha) or (beta).
Alpha-phellandrene is often characterized as having a citrus, herbal, black
pepper-like odor. Beta-
phellandrene is often characterized as having a peppery-minty and slightly
citrusy odor with a slight
minty-turpentine note.
73
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "phenylacetaldehyde" refers to a compound with the
following
structural formula:
H
,
I a
,--'"--
Phenylacetaldehyde is often characterized as having a strong pungent honey-
like sweet and green
floral odor. Phenylacetaldehyde is found in buckwheat, chocolate, and many
other foods and
flowers.
As used herein, the term "phenylethanethiol" refers to a compound with the
following
chemical formula: C81-110S comprising of multiple isomers.
Within the context of this disclosure, phenylethanethiol refers to any of the
isomers as a
pure compound and/or in any mixture. Phenylethanethiol is often characterized
as having the high
strength odor of rubber.
As used herein, the term "phenylacetic acid" refers to a compound with the
following
structural formula:
a,... ............... 0
Phenylacetic acid is often characterized as having a sour yet sweet, waxy,
civet, honey, rosey, floral
odor similar to honeysuckle with notes of chocolate and tobacco. Phenylacetic
acid is also used in
cosmetics for perfuming.
As used herein, the term "phytol" refers to a compound with the following
structural
formula:
oi.
Phytol is often characterized having a mild floral, balsamic, and green tea
type of aroma.
As used herein, the term "alpha-pinene" refers to a compound with either of
the following
structural formulas:
=
(-) and ( ).
Alpha-Pinene is often characterized as having a pine tree like aroma.
74
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "beta-pinene" refers to a terpene with the following
structural
formula:
/ .
Beta-Pinene is often characterized as having a woody-green pine-like smell.
Beta-Pinene is one of
the most abundant compounds released by forest trees. Beta-Pinene is an isomer
of pinene.
As used herein the term "pristimerin" refers to a compound with the following
structural
formula:
cs,.,=
.CHõ V. ...
Itsf=----9,k14::
.,õ,.......
1
fri:
= ' 440*,..,
.0 . . . =
... : = .... = = '''-`,.,õ,...,---7` ..^-,õ-^I'''",s."''.
.= = : ..-7'"`N.,.. = .. . = .7.7".... = . ''''
HO. .
Pristimerin is often characterized as having antiviral and antitumor
properties. Pristimerin is also
called celastrol methyl ester celastrol.
As used herein, the term "pulegone" refers to a compound with the following
structural
formula:
. 0
..
. .
PH3 -
µ
0113:
Pulegone is often characterized as having a smell similar to peppermint.
As used herein, the term "quercetin" refers to a compound with the following
structural
formula:
,
pki.
= ... .",,,,,, .. . . " =
1
=HO . 11011 .. = = :.: = p *... ..
. . = :.= .,.....
.1
P.4 .
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
As used herein, the term "retinol" refers to a compound with the following
structural
formula:
ti-s =ctis=CH, CK3
7
om
i
Retinol is often characterized as a type of vitamin A that can be converted to
other types of vitamin
A.
As used herein, the term "rutin" refers to a compound with the following
structural formula:
........a: ..,....õ,...,... oti
1
.....I.T....õ4õ), Ho. õ.,......õ..........,
___.....o.,,,,____ ..,,õ 08
1 T i om
..,,,,,... ____
44....-41----4.
OH 0 ')C3
crau------7"---o----
/
Ho
cm .
Rutin is often characterized as citrus flavonoid and found in many plants.
As used herein, the term "sabinene" refers to a compound with the following
structural
formula:
ht2
i
clia v
CHs .
Sabinene is often characterized as having a peppery, woody, herbaceous, and
spicy pine odor with
citrus notes. Sabinene is found in oak trees, tea tree oil, black pepper and
is a major constituent of
carrot seed oil. Within the context of this disclosure, the term sabinene
refers to either a
enantiomeric form or a mixture in any ratio.
As used herein, the term "sabinene hydrate" refers to a compound with the
following
structural formula:
H
H
76
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Sabinene hydrate is often characterized as haying an herbal, minty,
eucalyptol, and terpy odor with
a spicy nuance.
As used herein, the term "cis-sabinene hydrate" refers to a compound with the
following
structural formula.
HO
<
..,t4sti$
Cis-sabinene hydrate is often characterized as haying a balsamic odor.
As used herein, the term "trans-sabinene hydrate" refers to the following
structural formula.
OH
C, -,......õ,
-
-----..õ .....-----
--,,,--
Trans-sabinene hydrate is often characterized as haying a woody, balsamic
odor.
As used herein, the term "safranal" refers to a compound the following
structural formula:
CH a C.H.
/
.õ----.õ
--õ -..1.1
1
Safranal is often characterized as the component primarily responsible for the
aroma of saffron.
As used herein, the term "alpha-selinene" refers to a compound with the
following
structural formula:
,
ILI Alpha-selinene is often characterized as haying a distinct odor of amber.
Alpha-selinene is one of
the principal components of the oil from celery seeds.
As used herein, the term "alpha-sinensal" refers to a compound with the
following
structural formula:
O.
Alpha-sinensal is often characterized as haying a citrus orange, mandarin
aroma.
77
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
As used herein, the term "beta-sinensal" refers to a compound with the
following structural
formula:
Beta-sinensal is often characterized as having a sweet, fresh, waxy, and
citrus odor. Beta-sinensal
is used in fragrances.
As used herein, the term "beta-sitosterol" refers to a compound with the
following structural
formula:
--
--
isõ
- 1:
44,..
=:-''
*3
14 ifi.
õ.........), j
Beta-sitosterol is found in pecans, avocados, pumpkin seeds, cashews, corn
oils, and soybeans.
As used herein, the term "squalene" refers to a compound with the following
structural
formula:
N N. N.,
N. N. N
= .
Squalene is often characterized as playing an important part in the synthesis
of plant and animal
sterols.
As used herein, the term "taxadiene" refers to a compound with the following
structural
formula:
,
-----'e
, ,...-----;---
ill
Taxadiene is an intermediate in the synthesis of taxol.
As used herein, the term "terpin" refers to a compound of the following
structural formula:
78
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
OH
As used herein the term "terpineol" refers to a compound with the following
structural
formula:
Within the context of this disclosure, terpineol includes any of the isomeric
forms either as a single
form or a mixture in any ratio. Terpineol is used extensively in the perfume
industry. Within the
context of this disclosure, terpineol refers to any and all isomeric forms,
alpha, beta, gamma, etc,
in any ratio or combination,
As used herein, the term "terpinen-4-ol" refers to the isomer of terpineol
that has the
following structural formula:
Terpinen-4-ol is often characterized as having an herbaceous, peppery, woody
odor and is used in
commercial fragrances. Terpinen-4-ol is considered the primary active
ingredient of tea tree oil.
As used herein, the term "alpha-terpinene" refers a compound the following
structural
formula:
79
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Alpha-terpinene is often characterized as having a lemony-citrus aroma. Alpha-
terpinene has been
isolated from cardamom and marjoram oils.
As used herein, the term "gamma-terpinene" refers to a compound with the
following
structural formula:
Ji
Gamma-terpinene is often characterized as having an herbaceous, citrusy sweet
aroma.
As used herein, the term "terpinolene" or "delta-terpinene" refers to a
compound with the
following structural formula:
Terpinolene is often characterized as having an herbal aroma. Terpinolene's
flavor has been
described as sweet, woody, lemon, and lime-like.
As used herein, the term "thiophenol" refers to a compound with the following
structural
formula:
SH
Thiophenol is often characterized as having a sulfurous odor.
As used herein, the term "thujone" refers to a compound with either of the
following
structural formulas:
H 0
CH
or 3 3 =
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Within the context of this closure, the term "thujone" refers to any of the
isomeric forms in a pure
form or mixture of any ratio. Thujone is often characterized as having a
menthol like odor.
As used herein, the term "thymol" refers to a compound with the following
structural
formula:
cm,
11
_.............õ
Thymol is often found in oil of thyme.
As used herein, the term "alpha-tocopherol" refers to a compound with the
following
structural formula:
,
,
,
,
. .
Alpha-tocopherol is often characterized as having a very bland, slight,
vegetable oil-like odor.
As used herein, the term "tonka undecanone" refers to a compound with the
following
structural formula:
\\<.....,...,_,..
3 o ------ .
Tonka undecanone is often characterized as having a sweet, spicy, balsamic,
and Tonka woody
tobacco aroma.
As used herein, the term "undecanal" refers to an aldehyde that has the
following structural
formula:
"0
Undecanal is often characterized as having a soapy, aldehydic, waxy, and
slightly effervescent
orangey citrus-like odor with a watermelon, pineapple and cilantro background.
Undecanal is a
common component of perfumes.
As used herein, the term "valeraldehyde" or "pentanal" refers to a compound
with the
following structural formula:
81
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Valeraldehyde is often characterized as having a fermented type, diffusive,
bready, fruity odor with
berry nuances. Used as a flavoring agent, valeraldehyde has a wine-like,
fermented, bready, cocoa
flavor with chocolate notes.
As used herein, the term "verdoxan" refers to a cyclic ether with the
following structural
formula:
Verdoxan is often characterized as having a medium strength odor of earthy,
fruity, green, herbal,
sawn old wood. Verdoxan is used in fragrances and cosmetics.
As used herein, the term "alpha-ylangene" refers to a compound with the
following
structural formula:
Alpha-ylangene is often characterized as having a spicy, fruity aroma. Alpha-
ylangene is a natural
substance often found in wine and is emitted by some plants.
As used herein, the term "umbelliferone" refers to a compound with the
following structural
formula:
= 0 0
As used herein, the term "vanillin" refers to a compound with the following
structural
formula:
ctia
OH
'0
82
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Vanillin is often characterized as having a pleasant, sweet aroma, and the
characteristic vanilla-like
flavor.
Disclosed herein are new compositions comprising unique combinations of a
first purified
cannabinoid and a first purified terpene. In one embodiment, the first
purified cannabinoid and first
purified terpene are present in non-naturally occurring concentrations. In one
embodiment, the first
purified cannabinoid and first purified terpene are present in non-naturally
occurring ratios. In one
embodiment, the compositions disclosed herein provide particular benefits
previously unavailable
with naturally occurring cannabinoid and/or terpene profiles, such as those
found in plants,
harvested flowers, extracts, or conventional products derived from the same.
In one embodiment, the said combination of a first purified cannabinoid and a
first purified terpene
provide a synergistic effect at a mammalian cellular receptor, such as a G
protein coupled receptor.
In one embodiment, the receptor is CB1. In one embodiment, the receptor is
CB2. In one
embodiment, the receptor is GPR55. In one embodiment, the receptor is 5HT-1A.
In one
embodiment, the receptor is 5HT-2A. In one embodiment, the receptor is TRPV 1.
In one
embodiment, the receptor is an opioid receptor, e.g., p.-opioid receptor.
Disclosed herein is a composition comprising:
a first purified cannabinoid, chosen from THC, D9-THC, D8-THC, THCA, THCV,
D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV,
CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND,
CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or
CBLVA; and
a first purified terpene chosen from Limonene, Nerolidol, Beta-Myrcene,
Linalool,
Alpha-Caryophyllene, Beta-Caryophyllene, Alpha-Pinene, Beta-Pinene, Alpha-
Bisabolol,
Delta-3-Carene, Borneo', p-Cymene, Eucalyptol, Alpha-Humulene, Alpha-
Terpineol,
Terpinolene, Pulegone, Camphene, or Geraniol.
Within the context of this disclosure, using "combination of a first purified
cannabinoid
and a first purified terpene" may be accomplished by a formulating a
homogeneous mixture prior
to consuming (e.g., combusting, vaporizing, inhaling, or ingesting) the
mixture.
In one embodiment, the compositions disclosed herein are combined with a
carrier oil.
As used herein, the term "carrier oil" refers to a substance facilitating the
administration of
the compositions disclosed herein. In one embodiment, the carrier oil is
grapeseed oil. In one
embodiment, the carrier oil is coconut oil. In one embodiment, the carrier oil
is polyethylene
glycol.
As used herein, the term "polyethylene glycol" refers to a compound with the
following
structural formula:
83
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
teL
H 11 ''"----4n0
,
wherein n is an integer.
Polyethylene glycol is also known as PEG, polyethylene oxide (PEO), and
polyoxyethylene
(POE).
In one embodiment, the purified components disclosed herein are purposefully
chosen for
a desired effect. In one embodiment, the purposefully chosen purified
components are then
combined with a carrier oil. In a further embodiment, the purposefully
purified components in the
carrier oil is combined with a food product. In a further embodiment, the
purposefully purified
components in the carrier oil is combined with a beverage product. In a
further embodiment, the
purposefully purified components in the carrier oil is combined with a
personal care product, e.g.,
topical cream, soap, shampoo, etc. In a further embodiment, the purposefully
purified components
in the carrier oil is combined with a drug. In a further embodiment, the
purposefully purified
components in the carrier oil is combined with a plant extract. In a further
embodiment, the
purposefully purified components in the carrier oil is used with a device,
e.g., vaporizer,
intravenous drug, etc. In a further embodiment, the purposefully purified
components in the carrier
oil is used in combination with any of the above-mentioned embodiments.
In one example, particular purified components, such as purified terpenes, may
be added to
purified or unpurified cannabinoids to create the compositions disclosed
herein at the time of use.
Within the context of this disclosure the term "use" includes consuming via
ingestion or
heating and inhaling by, for example, combusting or vaporizing.
In one example, particular purified components, such as purified terpenes, may
be added to
purified or unpurified cannabinoids to create the compositions disclosed
herein at the time of use.
Within the context of this disclosure the term "use" includes consuming via
ingestion or heating
and inhaling by, for example, combusting or vaporizing.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Alpha-C aryophyllene.
84
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is THC and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Linalool.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Delta-3 -Carene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is D9-THC and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Beta-Myrcene.
86
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Delta-3 -Carene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is D8-THC and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Nerolidol.
87
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is THCA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Limonene.
88
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is THCV and the first
purified terpene is
Geraniol.
89
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Camphene.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is THCVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Delta-3-Carene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Pulegone.
91
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBD and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Terpinolene.
92
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBDA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Alpha-Humulene.
93
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBDV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Alpha-Terpineol.
94
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is C amphene.
In one embodiment, the first purified cannabinoid is CBDVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
p-Cymene.
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBC and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Eucalyptol.
96
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBCA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Delta-3-Carene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Borneo!.
97
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBCV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Delta-3 -C arene.
98
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBCVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Alpha-Bisabolol.
99
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Delta-3-Carene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBG and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Beta-Pinene.
100
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBGA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Alpha-Pinene.
101
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBGV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Beta-Caryophyllene.
102
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBGVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Alpha-Caryophyllene.
103
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBN and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Linalool.
104
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBNA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Beta-Myrcene.
105
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBNV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Nerolidol.
106
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBNVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Limonene.
107
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBND and the first
purified terpene is
Geraniol.
108
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Camphene.
109
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNDA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Pulegone.
110
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBNDV and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Delta-3 -C arene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Terpinolene.
111
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBNDVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Delta-3-Carene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Alpha-Humulene.
112
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBL and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Alpha-Terpineol.
113
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Camphene .
In one embodiment, the first purified cannabinoid is CBLA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Nerolidol.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Alpha- C aryophyllene .
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Beta-C aryophyllene .
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Alpha-Pinene .
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Delta- 3 -Carene .
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
p-Cymene.
114
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBLV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Nerolidol.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Delta-3 -Carene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Eucalyptol.
115
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBLVA and the first
purified terpene
is Geraniol.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Nerolidol
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Delta-3-Carene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Borneo!.
116
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBE and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Nerolidol
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Beta-C aryophyllene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Delta- 3 -C arene .
117
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Camphene .
In one embodiment, the first purified cannabinoid is CBEA and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Limonene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Nerolidol
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Linalool.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Alpha- C aryophyllene .
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Beta-C aryophyllene .
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Alpha-Pinene .
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Beta-Pinene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Alpha-Bisabolol.
118
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Delta- 3 -C arene .
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Borneo!.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Eucalyptol.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
p-Cymene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Terpinolene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Pulegone.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Camphene.
In one embodiment, the first purified cannabinoid is CBEV and the first
purified terpene is
Geraniol.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Limonene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Nerolidol
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Beta-Myrcene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Linalool.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Alpha-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Beta-Caryophyllene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Alpha-Pinene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Beta-Pinene.
119
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Alpha-Bisabolol.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Delta-3-C arene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Borneo!.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Eucalyptol.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is p-Cymene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Alpha-Terpineol.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Alpha-Humulene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Terpinolene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Pulegone.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Camphene.
In one embodiment, the first purified cannabinoid is CBEVA and the first
purified terpene
is Geraniol.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the first purified terpene comprise between 80-100% of the total mass of the
composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the first purified terpene comprise between 85-100% of the total mass of the
composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the first purified terpene comprise between 90-100% of the total mass of the
composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the first purified terpene comprise between 95-100% of the total mass of the
composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the first purified terpene comprise between 99-100% of the total mass of the
composition.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene is greater than 100:1, for example between 100:1
and 500:1.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene is between 100:1 to 10:1.
120
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 20:1 to 10:1.
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 10:1 to 1:1.
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 5:1 to 1:1.
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 3:1 to 1:1.
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 1:1 to 1:10.
In one embodiment of the disclosed composition, the ratio of purified
cannabinoid to
purified terpene is between 1:10 to 1:100.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 300:1 to 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 250:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 200:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 150:1 to 30:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 100:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Pinene of between 75:1 to 40:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of greater than 2:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of between 2:1 and 4:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of between than 4:1 and 16:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of between than 16:1 and 32:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of between than 32:1 and 64:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Pinene to CBG of greater than 100:1.
121
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 625:1 to 55:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Eucalyptol of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of greater than 0.625:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of between 0.625:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of between 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of between 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of between 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of between 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Eucalyptol to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 400:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 350:1 to 20:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 300:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 250:1 to 30:1.
122
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 200:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 150:1 to 40:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Humulene of between 100:1 to 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of greater than 1.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of between 1.5:1 and 3:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of between than 3:1 and 9:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of between than 9:1 and 27:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of between than 27:1 and 81:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Humulene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 625:1 to 55:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Linalool of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of greater than 0.625:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of between 0.625:1 and 5:1.
123
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Linalool
to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 350:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 300:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 250:1 to 20:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 200:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 150:1 to 30:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 100:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Limonene of between 85:1 to 40:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of greater than 3.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of between 3.5:1 and 7:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of between than 7:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of between than 75:1 and 100:1.
124
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Limonene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Nerolidol of between 150:1 to 4:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Nerolidol of between 120:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Nerolidol of between 60:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Nerolidol of between 30:1 to 20:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of greater than 3:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of between 3:1 and 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of between than 10:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Nerolidol to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Caryophyllene of between 150:1 to 4:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Caryophyllene of between 120:1 to 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Caryophyllene of between 60:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Caryophyllene of between 30:1 to 20:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of greater than 3:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of between 3:1 and 10:1.
125
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of between than 10:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Caryophyllene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 300:1 to 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 250:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 200:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 150:1 to 30:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 100:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Pinene of between 75:1 to 40:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of greater than 2:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of between 2:1 and 4:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of between than 4:1 and 16:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of between than 16:1 and 32:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of between than 32:1 and 64:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Pinene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 200:1 to 3:1.
126
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 175:1 to 7.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 150:1 to 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 125:1 to 12.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 100:1 to 15:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 75:1 to 17.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Beta-Myrcene of between 50:1 to 20:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of greater than 3:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of between 3:1 and 10:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of between than 10:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Beta-
Myrcene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 2,000:1 to 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 1,750:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 1,500:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 1,250:1 to 125:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 1,000:1 to 150:1.
127
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 750:1 to 175:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Alpha-Terpineol of between 500:1 to 200:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of greater than 0.3:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between 0.3:1 and 1:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between 0.3:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Alpha-
Terpineol to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 1,200:1 to 30:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 1,000:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 900:1 to 60:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 750:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 600:1 to 90:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 425:1 to 105:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Terpinolene of between 350:1 to 120:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of greater than 0.5:1.
128
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 0.5:1 and 1:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 1:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of between 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Terpinolene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 1,200:1 to 30:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 1,000:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 900:1 to 60:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 750:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 600:1 to 90:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 425:1 to 105:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Pulegone of between 350:1 to 120:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of greater than 0.5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 0.5:1 and 1:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 1:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 5:1 and 25:1.
129
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of between 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Pulegone to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 625:1 to 55:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Camphene of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of greater than 0.625:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of between 0.625:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified
Camphene to CBG of greater than 100:1.
130
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 625:1 to 55:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Delta-3-Carene of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of greater than 0.625:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of between 0.625:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of between than 50:1 and 75:1
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Delta-
3-Carene to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 625:1 to 55:1.
131
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
Geraniol of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of greater than 0.625:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of between 0.625:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified Geraniol
to CBG of greater than 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 950:1 to 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 875:1 to 35:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 750:1 to 45:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 625:1 to 55:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 500:1 to 65:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 350:1 to 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of THC
to purified
p-Cymene of between 240:1 to 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of greater than 0.625:1.
132
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of between 0.625:1 and 5:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of between than 5:1 and 25:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of between than 25:1 and 50:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of between than 50:1 and 75:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of between than 75:1 and 100:1.
In one embodiment, the compositions disclosed herein comprise a ratio of
purified p-
Cymene to CBG of greater than 100:1.
In one embodiment, the above described combinations of a first purified
cannabinoid and
a first purified terpene include a second purified cannabinoid chosen from
THC, D9-THC, D8-
THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC,
CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND,
CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.
Accordingly, disclosed herein are new compositions comprising unique
combinations of a
first purified cannabinoid, a second purified cannabinoid, and a first
purified terpene. In one
embodiment, the compositions disclosed herein comprise a first purified
cannabinoid, a second
purified cannabinoid, and a first purified terpene present in non-naturally
occurring concentrations.
In one embodiment, the compositions disclosed herein comprise a first purified
cannabinoid, a
second purified cannabinoid, and a first purified terpene present in non-
naturally occurring ratios.
In one embodiment, the compositions disclosed herein provide particular
benefits previously
unavailable with naturally occurring cannabinoid profiles, such as those found
in plants, harvested
flowers, extracts, or conventional products derived from the same.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the second purified cannabinoid to the first purified terpene is greater
than 100:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 100:1:1 to
10:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 20:1:1 to
10:1:1.
133
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 10:1:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 5:1:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 3:1:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:1:1 to
1:1:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:1:10 to
1:1:100.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 100:50:1 to
10:5:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 50:10:1 to
5:2:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 25:15:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:1:1 to
1:5:5.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:5:5 to
1:25:100.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 100:100:1
to 10:10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 20:20:1 to
10:10:1.
134
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 10:10:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 5:5:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 3:3:1 to
1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:1:1 to
1:10:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the first purified terpene
is between 1:10:10 to
1:100:100.
In one embodiment of the disclosed composition, the first purified
cannabinoid, the second
purified cannabinoid, and the first purified terpene, together, comprise
between 80-100% of the
total mass of the composition.
In one embodiment of the disclosed composition, the first purified
cannabinoid, the second
purified cannabinoid, and the first purified terpene, together, comprise
between 85-100% of the
total mass of the composition.
In one embodiment of the disclosed composition, the first purified
cannabinoid, the second
purified cannabinoid, and the first purified terpene, together, comprise
between 90-100% of the
total mass of the composition.
In one embodiment of the disclosed composition, the first purified
cannabinoid, the second
purified cannabinoid, and the first purified terpene, together, comprise
between 95-100% of the
total mass of the composition.
In one embodiment of the disclosed composition, the first purified
cannabinoid, the second
purified cannabinoid, and the first purified terpene, together, comprise
between 99-100% of the
total mass of the composition.
In one embodiment, the above described combinations of a first purified
cannabinoid and
a first purified terpene include a second purified terpene chosen from
Limonene, Nerolidol, Beta-
Myrcene, Linalool, Alpha-Caryophyllene, Beta-Caryophyllene, Alpha-Pinene, Beta-
Pinene,
Alpha-Bisabolol, Delta-3-Carene, Borneo', p-Cymene, Eucalyptol, Alpha-
Humulene, Alpha-
Terpineol, Terpinolene, Pulegone, Camphene, or Geraniol.
135
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Accordingly, disclosed herein are new compositions comprising unique
combinations of a
first purified cannabinoid, a first purified terpene, and a second purified
terpene are present in non-
naturally occurring concentrations. In one embodiment, the first purified
cannabinoid, the first
purified terpene, and second purified terpene are present in non-naturally
occurring ratios. In one
embodiment, the compositions disclosed herein provide particular benefits
previously unavailable
with naturally occurring cannabinoid profiles, such as those found in plants,
harvested flowers,
extracts, or conventional products derived from the same.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene is greater than
100:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 100:1:1 to 10:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 20:1:1 to 10:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 10:1:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 5:1:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 3:1:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:1:1 to 1:1:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:1:10 to 1:1:100.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 100:50:1 to
10:5:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 50:10:1 to 5:2:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 25:15:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:1:1 to 1:5:5.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:5:5 to 1:25:100.
136
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 100:100:1 to
10:10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 20:20:1 to
10:10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 10:10:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 5:5:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 3:3:1 to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:1:1 to 1:10:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the first purified terpene to the second purified terpene is
between 1:10:10 to
1:100:100.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene, together,
comprise between 80-100% of
the total mass of the composition.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene, together,
comprise between 85-100% of
the total mass of the composition.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene, together,
comprise between 90-100% of
the total mass of the composition.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene, together,
comprise between 95-100% of
the total mass of the composition.
In one embodiment of the disclosed composition, the ratio of the first
purified cannabinoid
to the first purified terpene to the second purified terpene, together,
comprise between 99-100% of
the total mass of the composition.
Disclosed herein are new compositions comprising combinations of a first
purified
cannabinoid and a second purified cannabinoid. In one embodiment, compositions
disclosed herein
are manmade. In one embodiment, the first purified cannabinoid and the second
purified
cannabinoid are present in non-naturally occurring concentrations. In one
embodiment, the first
137
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
purified cannabinoid and the second purified cannabinoid are present in non-
naturally occurring
ratios. In one embodiment, the compositions disclosed herein provide
particular benefits previously
unavailable with naturally occurring cannabinoid profiles, such as those found
in plants, harvested
flowers, extracts, or conventional products derived from the same.
In one embodiment, the said combination of a first purified cannabinoid and a
second
purified cannabinoid provide a synergistic effect at a mammalian cellular
receptor, such as a G
protein coupled receptor. In one embodiment, the receptor is CB1. In one
embodiment, the receptor
is CB2. In one embodiment, the receptor is GPR55. In one embodiment, the
receptor is 5HT-1A.
In one embodiment, the receptor is 5HT-2A. In one embodiment, the receptor is
TRPV1. In one
embodiment, the receptor is an opioid receptor, e.g., p.-opioid receptor.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is greater than 100:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 100:1 to 10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 20:1 to 10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 10:1 to 1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 5:1 to 1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 3:1 to 1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid is between 1:1 to 1:10.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the second purified cannabinoid comprise between 80-100% of the total mass of
the composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the second purified cannabinoid comprise between 85-100% of the total mass of
the composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the second purified cannabinoid comprise between 90-100% of the total mass of
the composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the second purified cannabinoid comprise between 95-100% of the total mass of
the composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid and
the second purified cannabinoid comprise between 99-100% of the total mass of
the composition.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is D8-THC.
138
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is THCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is THCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is THCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBD.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBDA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBNV.
139
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D9-THC and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is THCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is THCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is THCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBD.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBDA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBNA.
140
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
D8-THC and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is THCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is THCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBD.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBDA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBNA.
141
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is THCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBD.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBDA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBNV.
142
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCV and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBD.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBDA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
THCVA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBDA.
143
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBD and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBDV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBCA.
144
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBDVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBGV.
145
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDV and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBC.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBDVA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBCA.
146
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBC and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBCV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBNA.
147
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBCVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCV and the second purified cannabinoid is CBCA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBG.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBNA.
148
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBCVA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBGA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBG and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBGV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBGVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGV and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGV and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGV and the second purified cannabinoid is CBNV.
149
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGV and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGVA and the second purified cannabinoid is CBN.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGVA and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGVA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBGVA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBN and the second purified cannabinoid is CBNA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBN and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBN and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBNA and the second purified cannabinoid is CBNV.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBNA and the second purified cannabinoid is CBNVA.
In one embodiment of the compositions disclosed herein, the first purified
cannabinoid is
CBNV and the second purified cannabinoid is CBNVA.
In one embodiment, the above described combinations of a first purified
cannabinoid and
a second purified cannabinoid include a third purified cannabinoid chosen from
THC, D9-THC,
D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC,
CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND,
CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.
Accordingly, disclosed herein are new compositions comprising unique
combinations of a
first purified cannabinoid, a second purified cannabinoid, and a third
purified cannabinoid. In one
embodiment, the compositions disclosed herein comprise a first purified
cannabinoid, a second
purified cannabinoid, and a third purified cannabinoid present in non-
naturally occurring
concentrations. In one embodiment, the compositions disclosed herein comprise
a first purified
cannabinoid, a second purified cannabinoid, and a third purified cannabinoid
present in non-
naturally occurring ratios. In one embodiment, the compositions disclosed
herein provide particular
benefits previously unavailable with naturally occurring cannabinoid profiles,
such as those found
in plants, harvested flowers, extracts, or conventional products derived from
the same.
150
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is greater than
100:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 100:1:1
to 10:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 20:1:1
to 10:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 10:1:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 5:1:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 3:1:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:1:1
to 1:1:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:1:10
to 1:1:100.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between
100:50:1 to 10:5:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 50:10:1
to 5:2:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 25:15:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:1:1
to 1:5:5.
151
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:5:5
to 1:25:100.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between
100:100:1 to 10:10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 20:20:1
to 10:10:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 10:10:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 5:5:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 3:3:1
to 1:1:1.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:1:1
to 1:10:10.
In one embodiment of the compositions disclosed herein, the ratio of the first
purified
cannabinoid to the second purified cannabinoid to the third purified
cannabinoid is between 1:10:10
to 1:100:100.
EXAMPLES
The following examples are provided as non-limiting illustrations of the
broader disclosure.
Example 1:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Beta-Pinene (0.8 g).
Example 2:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Geraniol (0.5 g).
Example 3:
A composition was formulated by combining the following components: purified
THC (99
g) and purified p-Cymene (0.5 g).
152
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Example 4:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Delta-3-Carene (0.25 g).
Example 5:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Camphene (0.375 g).
Example 6:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Pulegone (0.3 g).
Example 7:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Terpinolene (0.3 g).
Example 8:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Alpha-Terpineol (0.2 g).
Example 9:
A composition was formulated by combining the following components: purified
THC (98
g) and purified Beta-Myrcene (1.25 g).
Example 10:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Alpha-Pinene (0.8 g).
Example 11:
A composition was formulated by combining the following components: purified
THC (98
g) and purified Beta-Caryophyllene (1.5 g).
Example 12:
A composition was formulated by combining the following components: purified
THC (98
g) and purified Nerolidol (1.5 g).
Example 13:
A composition was formulated by combining the following components: purified
THC (97
g) and purified Limonene (1.4 g).
Example 14:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Linalool (0.375 g).
Example 15:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Beta-Pinene (0.8 g).
153
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Example 16:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Eucalyptol (0.5 g).
Example 17:
A composition was formulated by combining the following components: purified
THC (99
g) and purified Alpha-Humulene (0.9 g).
Example 18:
A composition was formulated by combining the following components: purified
THC (51
g), purified CBD (10 g), purified CBG (4 g), purified Linalool (0.5 g),
purified Limonene (0.5 g),
and purified Alpha-Humulene (0.5 g).
Example 19:
A composition was formulated by combining the following components: purified
THC (50
g), purified THCV (10 g), purified CBG (4 g), purified CBC (0.2 g), purified
Beta-Pinene (2 g),
purified Beta-Caryophyllene (0.5 g), purified Limonene (1 g), and purified
Eucalyptol (0.25 g).
Example 20:
A composition was formulated by combining the following components: purified
THC (20
g); purified CBC (10 g); purified CBN (0.2 g); purified THCV (0.6 g); and
purified Beta-Pinene
(0.8 g).
Example 21:
A composition was formulated by combining the following components: purified
THC (51
g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified
THCV (0.6 g);
purified Beta-Caryophyllene (1.6 g); and purified Alpha-Terpineol (0.16 g).
Example 22:
A composition was formulated by combining the following components: purified
THC (51
g), purified Beta-Pinene (1 g), purified Alpha-Terpineol (0.1 g), and purified
Linalool (0.1 g).
Example 23:
A composition was formulated by combining the following components: purified
THC (51
g), purified Beta-Pinene (1 g), purified Alpha-Terpineol (0.1 g), purified
Linalool (0.1 g), and
Polyethylene Glycol (25 g).
Example 24:
A composition was formulated by combining the following components: purified
THC (51
g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified
THCV (0.6 g);
purified Beta-Caryophyllene (1 g); and purified Linalool (0.1 g).
Example 25:
A composition was formulated by combining the following components: purified
THC (51
g), purified Alpha-Pinene (1.6 g) and purified Linalool (0.25 g).
154
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Example 26:
A composition was formulated by combining the following components: purified
THC (51
g), purified Alpha-Pinene (1.6 g), purified Linalool (0.25 g), and purified
Alpha-Humulene (0.6 g).
Example 27:
A composition was formulated combining the following components: purified THC
(51 g),
purified Linalool (0.5 g), purified Alpha-Pinene (0.75 g), and purified
Eucalyptol (0.75 g).
Example 28:
A composition was formulated combining the following components: purified THC
(51 g),
purified Linalool (0.5 g), purified Alpha-Pinene (0.75 g), purified Eucalyptol
(0.75 g), and purified
Nerolidol (1.5 g).
Example 29:
A composition was formulated combining the following components: purified THC
(51 g),
purified Linalool (0.5 g), purified Alpha-Pinene (1.6 g), purified Eucalyptol
(0.75 g), and
Polyethylene Glycol (25 g).
Example 30:
A composition was formulated combining the following components: purified THC
(51 g),
purified Linalool (0.5 g), purified Alpha-Pinene (1.6 g), purified Eucalyptol
(0.75 g), purified
Terpinolene (0.25 g), and Polyethylene Glycol (25 g).
Example 31:
A composition was formulated combining the following components: purified THC
(51 g),
purified Beta-Caryophyllene (1 g), purified Alpha-Humulene (1 g), and
Polyethylene Glycol (25
g).
Example 32:
A composition was formulated combining the following components: purified THC
(51 g),
purified Beta-Caryophyllene (1 g), purified Alpha-Humulene (2 g), and
Polyethylene Glycol (25
g).
Example 33:
A composition was formulated combining the following components: purified THC
(51 g),
purified Beta-Caryophyllene (2 g), purified Alpha-Humulene (2 g), and
Polyethylene Glycol (25
g).
Example 34:
A composition was formulated combining the following components: purified THC
(75 g)
and purified THCV (5 g).
Example 35:
A composition was formulated combining the following components: purified THC
(50 g)
and purified CBD (10 g).
155
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Example 36:
A composition was formulated combining the following components: purified THC
(50 g)
and purified CBG (5 g).
Example 37:
A composition was formulated combining the following components: purified THC
(75 g)
and purified CBC (15 g).
Example 38:
A composition was formulated combining the following components: purified THC
(75 g)
and purified CBN (10 g).
Example 39:
A composition was formulated combining the following components: purified CBD
(50 g)
and purified Alpha-Bisabolol (50 g).
Example 40:
A composition was formulated combining the following components: purified CBC
(50 g)
and purified Alpha-Bisabolol (50 g).
Example 41:
A composition was formulated combining the following components: purified CBG
(50 g)
and purified Alpha-Bisabolol (50 g).
Example 42:
A composition was formulated combining the following components: purified CBD
(50 g),
purified CBC (50 g), and purified Alpha-Bisabolol (50 g).
Example 43:
A composition was formulated combining the following components: purified CBD
(50 g),
purified CBG (50 g), and purified Alpha-Bisabolol (50 g).
Example 44:
A composition was formulated combining the following components: purified CBC
(50 g),
purified CBG (50 g), and purified CBD (50 g).
Example 45:
A composition was formulated combining the following components: purified CBC
(50 g),
purified CBG (50 g), and purified CBN (50 g).
Example 46:
The clinical effects of terpene concentrations were measured by comparing the
differences
in response measured between (a) administering a purified cannabinoid alone
and (b) administering
the same purified cannabinoid in concert with a purified terpene. Each of the
following variables
were systematically evaluated: cannabinoid compound(s) present; terpene
compounds(s) present;
and their absolute and relative concentrations.
156
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
In each observational study, each participant was given a formulation having a
particular
chemical composition pursuant to the guidelines above. Subjective feelings
were scored on a Visual
Analogue Scale (VAS), in web-based survey questions, 60 minutes after subjects
start to vape a
sample. Each VAS question asked subjects to click on a horizontal bar at a
location that reflected
the degree to which their feelings were described by adjectives positioned at
either end of the bar.
Clicking at the left end of the bar returned a score of zero whereas clicking
at the right end returned
a score of 10. "Unipolar" questions asked subjects to report the strength of a
singular feeling on a
zero (not at all) to 10 (extremely) scale (Bowdle reference). "Bipolar"
questions were also scored
on a 0 to 10 scale. For bipolar questions, clicking in the middle of the bar
(score of 5) meant that
any given subject reported neutrality with respect to the adjectives
positioned at either end of the
bar.
Subjective feelings scores reported for each VAS survey question were
averaged, and mean
values were compared between base oil, and low and high terpene-enriched
samples. Sample sizes
in these experiments were low, yielding suggestive interpretations with regard
to feelings elicited
by terpene enrichment. Hence, the most prominent feelings elicited by terpene
enrichment were
identified according to conservative criteria: 1) when mean scores trended
toward a given VAS
adjective as terpene enrichment moved from zero to high percentage, and 2)
when mean scores
changed by at least 50% as they trended from low to high score.
The following table illustrates how clinical results may be organized to
compare trends in
particular feelings when studying terpene enrichment.
Terpene Elicited subjective Mean value from VAS survey question
enrichment feeling
Base oil Low High enrichment
enrichment
Eucalyptol Well-coordinated 4.7 3.7 3.0
More Anxious (U) 0.7 1.7 2.0
More Stoned (U) 1.7 3.0 3.0
Upset 2.3 3.7 3.7
Hungry 3.3 3.7 6.0
Troubled 7.7 6.3 4.7
157
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
Tense 7.0 6.3 4.7
Sad 2.7 2.7 4.7
Clearheaded 5.3 6.3 7.0
Beta-Pinene More Anxious (U) 1.0 2.5 7.5
More Paranoid (U) 0.5 2.5 7.5
Gloomy 8.0 6.0 2.5
Quiet 7.5 6.5 2.5
Sluggish 2.0 3.5 7.5
Moistmouth 7.5 6.5 2.5
Uninspired 1.5 3.5 7.5
Cautious 7.5 6.0 2.5
Uninventive 2.0 4.0 7.5
Upset 1.0 2.5 7.5
Restless 9.0 7.5 2.5
Drowsy 3.0 3.5 6.0
Discontented 1.5 2.5 7.5
Sad 2.0 2.5 6.5
Bored 1.0 2.5 6.5
Agitated 2.0 2.5 7.5
Alpha-Pinene Attentive 0.0 3.0 5.0
158
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Alpha-Humulene More Stoned (U) 0 61 74
More High (U) 0 45 60
Passing of time is 0 32 51
altered more (U)
Heavenly 51 36 17
Interested 61 32 17
Excited 39 43 73
Headhigh 51 51 16
Limonene Drowsy 6 23 30
Drymouth 46 67 84
Linalool Interested 55 49 31
Happy 19 28 29
Gregarious 38 53 60
Creative 58 41 34
In the moment 46 56 67
Nerolidol Less Stoned (U) 75 68 54
Less Anxious (U) 67 42 28
Less Paranoid (U) 68 38 28
Discontented 23 28 40
Mindful 37 52 61
159
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
Beta- Passing of time is 77 54 44
Caryophyllene altered (U)
Lazy 12 23 55
Disjointed 19 46 68
Confused 34 45 55
Dreamy 28 38 67
Bored 16 34 43
Sad 10 28 35
Calm 64 62 33
Discontented 23 28 40
Unaware 29 34 55
Chill 25 34 69
Bodyhigh 11 38 60
Depressed 21 32 36
Uncreative 34 38 67
Lethargic 67 60 39
Beta-Myrcene More Anxious (U) 6 10 26
More Drowsy (U) 20 30 44
More Paranoid (U) 1 10 34
Disjointed 24 37 40
Drymouth 31 38 47
160
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
Upset 28 38 43
Depressed 30 36 46
Alpha-Terpineol Intensity of sound 27 15 10
changes less (U)
Scattered 64 57 29
Confused 30 50 57
Drowsy 32 49 65
Unaware 28 44 54
Unproductive 14 44 59
Chill 29 57 81
Bodyhigh 24 34 68
Lethargic 63 44 31
Inattentive 70 51 42
Dull 30 55 61
Sluggish 33 56 61
Absent 24 50 60
Unsociable 38 59 66
Terpinolene Intensity of colors 28 41 54
changed more (U)
Heavenly 42 31 26
Creative 51 37 25
161
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
Talkative 76 53 42
Constructive 62 41 37
Uplifted 50 36 28
Inventive 48 34 29
Lively 70 48 39
More High (U) 35 49 57
The passing of time 14 17 34
is altered (U)
Intensity of sound 19 22 40
changed (U)
Bored 25 31 44
Discontented 17 21 33
Clearheaded 24 38 40
Bodyhigh 26 41 50
Pulegone Centered 47 34 31
Camphene Excited 26 39 44
Gregarious 32 52 61
Wild 21 27 36
Social 66 48 43
Delta-3-Carene More Drowsy (U) 12 14 36
Drymouth 47 60 72
162
CA 03054690 2019-08-26
WO 2018/160827 PCT/US2018/020440
Worried 24 29 38
Geraniol Less Paranoid (U) 23 8 3
Interested 45 37 27
Worried 16 22 27
Active 50 43 32
Headhigh 39 34 20
Restless 70 69 45
p-Cymene Less Anxious (U) 22 16 15
More Drowsy (U) 23 24 41
Interested 41 36 28
Calm 37 31 15
Laidback 33 28 18
Depressed 32 37 51
Mellow 44 52 68
Lethargic 64 58 37
Unsocial 32 34 57
These examples are meant to be non-limiting and serve only to illustrate
possible
embodiments of the formulations disclosed herein.
Although the present invention herein has been described with reference to
various
exemplary embodiments, it is to be understood that these embodiments are
merely illustrative of
the principles and applications of the present invention. Those having skill
in the art would
recognize that various modifications to the exemplary embodiments may be made,
without
departing from the scope of the invention.
163
CA 03054690 2019-08-26
WO 2018/160827
PCT/US2018/020440
Moreover, it should be understood that various features and/or characteristics
of differing
embodiments herein may be combined with one another. It is therefore to be
understood that
numerous modifications may be made to the illustrative embodiments and that
other arrangements
may be devised without departing from the scope of the invention.
Furthermore, other embodiments of the invention will be apparent to those
skilled in the art
from consideration of the specification and practice of the invention
disclosed herein. It is intended
that the specification and examples be considered as exemplary only, with a
scope and spirit being
indicated by the claims.
Finally, it is noted that, as used in this specification and the appended
claims, the singular
forms "a," "an," and "the," include plural referents unless expressly and
unequivocally limited to
one referent, and vice versa. As used herein, the term "include" or
"comprising" and its
grammatical variants are intended to be non-limiting, such that recitation of
an item or items is not
to the exclusion of other like items that can be substituted or added to the
recited item(s).
164
